Methods for treating T-lymphocyte-mediated diseases

Abstract

The present invention relates to the field of medicine, more specifically to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, the method comprising administering an anti-TRBV9 antibody using a specific dose and dosing regimen, and further to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, the anti-TRBV9 antibody being administered at a specific dose and dosing regimen.

Description

[Technical Field]

[0001] The present invention relates to the field of medicine, specifically to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, the method comprising administering an anti-TRBV9 antibody using a defined dose and dosing regimen; and to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, the anti-TRBV9 antibody being administered using a defined dose and dosing regimen. [Background technology]

[0002] Autoimmune diseases are caused by autoreactive T lymphocytes (Haroon N et al., Arthritis Rheum. 2013 Oct;65(10):2645-54; Duarte J. et al., PloS One 2010 May 10;5(5):e10558; Konig M. et al., Front Immunol 2016 Jan 25;7:11). The emergence of autoreactive T lymphocyte clones relies primarily on the interaction of antigen-recognizing T cell receptors (TCRs) with proteins of the major histocompatibility complex (MHC, HLA), which present processed peptides of intracellular proteins or proteins of pathogenic organisms on their surface. Several autoimmune diseases are associated with the presence of certain variants of HLA genes in humans. Thus, the HLA-B27 allele is associated with ankylosing spondylitis, reactive arthritis, and Crohn's disease. The risk of developing autoimmune diseases in carriers of certain HLA allele variants can be explained by the fact that these alleles preferentially present specific peptides that are self-antigens, and immune responses to these peptides trigger the onset of autoimmune diseases. One mechanism that may underlie autoimmune reactions is the presentation by histocompatibility complex molecules of peptides from proteins of bacterial or viral origin that are homologous to the organism's own peptides, which can result in an immune response to self-antigens as a result of cross-reactivity.

[0003] The prior art has shown that T cell receptor (TCR) sequences are markers that allow the identification of T lymphocyte clones involved in the pathogenesis of autoimmune diseases. T cell receptor subunits structurally belong to the immunoglobulin superfamily and are formed from several gene segments. The variable regions of the TCR form the antigen-binding center of the TCR. This means that they are clone-specific, i.e., they differ from those T lymphocytes that react with various antigens.

[0004] T lymphocytes (T cells) are stimulated when an antigen binds to their T cell receptor (TCR). The TCR, a key structure of T cells, is a transmembrane heterodimer consisting of either alpha and beta chains or delta and gamma chains linked by disulfide bonds. These chains contain complementarity-determining regions (CDRs), which determine the antigen to which the TCR binds. TCR development occurs through a lymphocyte-specific genetic recombination process that assembles the final sequence from multiple potential segments. This genetic recombination of TCR gene segments in somatic T cells occurs during early development in the thymus. The TCR α locus contains the variable (V) and joining (J) gene segments (Vβ and Jβ), while the TCR β locus contains the D gene segment in addition to the Vα and Jα segments. Thus, the α chain is generated by VJ recombination, and the β chain is involved in VDJ recombination.

[0005] The TCR α chain locus consists of 46 variable segments (TRAV), 8 joining segments (TRAJ), and a constant region. The TCR β chain locus consists of 48 variable segments (TRBV), followed by two diversity segments (TRBD), 12 joining segments (TRBJ), and two constant regions (Bio-Rad. Mini-review | An overview of T cell receptors [Electronic resource] / / Bio-Rad. URL: https: / / www.bio-rad-antibodies.com / t-cell-receptor-minireview.html (accessed: 24.04.2020)).

[0006] To date, a significant amount of data has accumulated demonstrating that the development of HLA-B27-associated diseases is due to the expansion of antigen-specific T lymphocyte clones. A consensus variant of autoimmune TCR has been described in ankylosing spondylitis (axial ankylosing spondylitis that meets radiological criteria); this variant has been shown to be present in the synovial fluid and peripheral blood of patients with ankylosing spondylitis, and to be absent in healthy donors at the same analytical depth, regardless of the status of the HLA*B27 allele (Faham M. et al., Arthritis Rheumatol. 2017; 69(4):774-784; Komech E et al. 12th EJI-EFIS Tatra Immunology Conference; 2016 Sep 3-7; Strbske Pleso, Slovakia. Abstract book p. 39). The TCR belongs to the TRBV9 family (according to the IMGT nomenclature).

[0007] T cell receptors with beta chains of the TRBV9 family have also been shown to be involved in the development of autoimmune diseases such as celiac disease (Petersen J et al., J Immunol. 2015;194(12):6112-22). They are also found on the surface of transformed T cells in T cell lymphomas and T cell leukemias, including those caused by Epstein-Barr virus (EBV) (Toyabe S et al., Clin Exp Immunol. 2003;134(1):92-97).

[0008] Considering the above, the TRBV9 protein is a key component of the TRBV9-containing pathogenic autoreactive T lymphocyte clones. + It can act as a target for cytotoxic monoclonal antibodies that induce depletion of T lymphocytes (TRBV9-positive T lymphocytes).

[0009] Therefore, there is a need to develop a method for treating a disease or disorder mediated by a human T cell receptor bearing TRBV9, comprising administering an anti-TRBV9 antibody using a defined dose and dosing regimen. Summary of the Invention [Means for solving the problem]

[0010] [Brief explanation of the drawings]

[0011] [Figure 1] Figure 1 shows a diagram of the main processes considered in the mathematical model: TCR - T cell receptor, Effector cell - effector cell. DETAILED DESCRIPTION OF THE INVENTION

[0012] definition Unless otherwise defined herein, all technical and scientific terms used in connection with the present invention have the same meaning as commonly understood by one of ordinary skill in the art.

[0013] Further, unless otherwise required by context, singular terms shall include plural terms and plural terms shall include the singular term. As used herein and in the claims that follow, unless the context dictates otherwise, the words "have," "include," and "comprise," or variations thereof, such as "has," "having," "includes," "including," "comprises," or "comprising," are understood to imply the inclusion of a stated integer or group of integers, but not the exclusion of any other integer or group of integers.

[0014] The term "antibody" or "immunoglobulin" (Ig) includes full-length antibodies or any antigen-binding fragment (i.e., "antigen-binding portion") or individual chains thereof. The term "antibody" within the scope of the present invention is used in the broadest sense and can include, but is not limited to, monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, humanized, fully human antibodies, and chimeric antibodies.

[0015] A full-length antibody refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain comprises a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The constant region is identical in all antibodies of the same isotype but differs in antibodies of different isotypes. Heavy chains γ, α, and δ each have a constant region composed of three constant domains, CH1, CH2, and CH3 (linear), as well as a hinge region for increased flexibility (Woof J., Burton D., Nat Rev Immunol 4, 2004, pp. 89-99). In mammals, only two types of light chains are known, designated lambda (λ) and kappa (κ). Each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The approximate length of a light chain is 211-217 amino acids. Preferably, the light chain is a lambda (λ) light chain, and the constant domain CL is preferably Clamda (λ).

[0016] The VL and VH regions can be further subdivided into hypervariable regions called complementarity-determining regions (CDRs), which are located between more conserved regions called framework regions (FRs). Each VH and VL is composed of three CDRs and four FRs, arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of an antibody can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.

[0017] The term "antigen-binding portion" or "antigen-binding fragment" of an antibody, as used herein, refers to one or more antibody fragments that retain the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. As used herein, the term "antigen-binding fragment" refers to a Fab fragment, i.e., a monovalent fragment consisting of the VL, VH, CL, and CH1 domains linked to an Fc fragment monomer.

[0018] The term "variable" refers to the fact that certain portions of the variable domains vary widely in sequence among different antibodies. The V domain mediates antigen binding and determines the specificity of each particular antibody for its particular antigen. However, variability is not uniformly distributed across the 110-amino acid length of the variable domain. Rather, the V region consists of invariant segments of 15-30 amino acids called framework regions (FRs) separated by shorter regions of extreme diversity called "hypervariable regions" or "CDRs." Naturally occurring heavy and light chain variable domains each contain four FRs, which adopt a primarily beta-sheet configuration connected by three hypervariable regions that form loops that connect, and in some cases form part of, the beta-sheet structure. The hypervariable regions of each chain are held together by the FRs and, together with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular cytotoxicity (ADCC).

[0019] The term "hypervariable region" according to the present specification refers to the amino acid residues of an antibody which are responsible for antigen-binding. Hypervariable regions typically comprise amino acid residues from the "complementarity-determining regions" or "CDRs", and / or residues from the "hypervariable loops".

[0020] The "Kabat numbering scheme" or "numbering according to Kabat" refers, in the present invention, to a system for numbering amino acid residues that are more variable than other amino acid residues (i.e., hypervariable) in the variable regions of the heavy and light chains of an antibody (Kabat et al. Ann. NY Acad. Sci., 190:382-93 (1971); Kabat et al. Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242 (1991)).

[0021] An antibody of the present invention that "binds" to a target antigen refers to an antibody that binds to the antigen with sufficient affinity so that it can be used as a diagnostic and / or therapeutic agent targeting proteins or cells or tissues expressing the antigen, and that cross-reacts to a small extent with other proteins. Analytical methods include fluorescence-activated cell sorting (FACS), radioimmunoassay (RIA), or ELISA. In such embodiments, the extent of antibody binding to non-target proteins is less than 10% of that to the specific target protein. With respect to antibody binding to a target molecule, the terms "specific binding" or "specifically binds" or "is specific for" a particular polypeptide or epitope on a particular target polypeptide refer to binding that is significantly (measurably) different from non-specific interactions.

[0022] Specific binding can be measured, for example, by determining the binding of a molecule compared to the binding of a control molecule.For example, specific binding can be determined by competition between a target, for example, an excess of unlabeled target and another molecule that is similar.In this example, specific binding is indicated if the binding of the labeled target to the probe is competitively inhibited by an excess of unlabeled target.As used herein, the term "specific binding" or "specifically binds" or "is specific" to a specific polypeptide or epitope on a specific target polypeptide can be illustrated by the example of a molecule that has a KD (affinity constant) for the target of at least about 200nM, or at least about 150nM, or at least about 100nM, or at least about 60nM, or at least about 50nM, or at least about 40nM, or at least about 30nM, or at least about 20nM, or at least about 10nM, or at least about 8nM, or at least about 6nM, or at least about 4nM, or at least about 2nM, or at least about 1nM, or more. In one aspect, the term "specifically binds" refers to binding when a molecule binds to a particular polypeptide or an epitope on a particular polypeptide without substantially binding to any other polypeptides or epitopes on polypeptides.

[0023] The term "monoclonal antibody" or "mAb" refers to an antibody that is synthesized and isolated as a discrete clonal population of cells. The term "recombinant antibody" refers to an antibody that is expressed in a cell or cell line that contains a nucleotide sequence encoding the antibody, wherein the nucleotide sequence is not naturally associated with the cell.

[0024] The term "isolated" as applied to describing various antibodies according to the present invention refers to an antibody that has been identified and isolated and / or recovered from the cell or cell culture in which it is expressed. Impurities (contaminating components) from the natural environment are materials that would typically interfere with diagnostic or therapeutic uses of the polypeptide and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. Isolated polypeptides are typically prepared by at least one purification step.

[0025] The terms "anti-TRBV9 antibody," "antibody against TRBV9," "antibody that specifically binds to the TRBV9 family beta chain," and "antibody against the TRBV9 family beta chain" are interchangeable within the scope of the present invention and relate to an antibody that specifically binds to an epitope of the TRBV9 family beta chain of the human T-cell receptor.

[0026] The term "main dose" refers to the recommended dose of an anti-TRBV9 antibody product, or the complete recommended dose of an anti-TRBV9 antibody product, or the recommended dose of an anti-TRBV9 antibody in the form of intravenous infusion, or the complete recommended dose of an anti-TRBV9 antibody product in the form of intravenous infusion.

[0027] The term "half the primary dose" refers to half the recommended dose of an anti-TRBV9 antibody product, or half the full recommended dose of an anti-TRBV9 antibody product, or half the recommended dose of an anti-TRBV9 antibody in the form of intravenous infusion, or half the full recommended dose of an anti-TRBV9 antibody product in the form of intravenous infusion.

[0028] The term "at least" in the context of administration refers to a minimum administration interval of ±2 days. "At least 3 months," when expressed as intervals of 3 months ±2 days increments, refers to administration after 3 months ±2 days, or 6 months ±2 days, or 9 months ±2 days, or 12 months ±2 days, etc. "At least 6 months," when expressed as intervals of 3 months ±2 days increments, refers to administration after 6 months ±2 days, or 9 months ±2 days, or 12 months ±2 days, etc. "At least 9 months," when expressed as intervals of 3 months ±2 days increments, refers to administration after 9 months ±2 days, or 12 months ±2 days, or 15 months ±2 days, etc. "At least 12 months," when expressed as intervals of 3 months ±2 days increments, refers to administration after 12 months ±2 days, or 15 months ±2 days, or 18 months ±2 days, etc.

[0029] The term "dosing interval" refers to the time interval between doses, with subsequent doses counted from the second or third infusion date and time, and each subsequent dose counted from the previous dose. The term "first administration" or "first infusion" refers to the initial dose or half of the main dose of an anti-TRBV9 antibody product.

[0030] The term "second administration" or "second infusion" refers to the administration of a main dose of an anti-TRBV9 antibody product at least three months after the first administration. The term "third administration" or "third infusion" refers to the administration of the main dose of an anti-TRBV9 antibody product at least three months after the second administration.

[0031] The term "subsequent administration" refers to administration of a main dose of an anti-TRBV9 antibody product at least three months after each previous administration. The term "use" refers to the possible use of an anti-TRBV9 antibody according to the present invention, or a pharmaceutical composition comprising the same, to treat a disease or disorder, alleviate its course, hasten remission, or reduce the recurrence rate of a disease or disorder.

[0032] The term "disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor" refers to any disease or disorder associated either directly or indirectly with T lymphocytes having a TRBV9 segment in their T cell receptor, including the etiology, onset, progression, persistence, or pathology of the disease or disorder.

[0033] The term "method of treatment" refers to the use of the antibodies of the present invention or pharmaceutical compositions containing them to treat diseases or disorders associated with the activity of T lymphocytes having a TRBV9 segment in their T cell receptor, alleviate the course of the disease, hasten remission, or reduce the relapse rate. "Treating" a disease, disorder, or condition, or "treatment," can include preventing or delaying the onset of clinical symptoms of the disease, disorder, or condition occurring in humans, inhibiting, i.e., halting, the onset of the disease or its recurrence (in the case of maintenance treatment), or reducing or delaying at least one clinical or subclinical symptom, or alleviating or palliating the disease, i.e., causing regression of the disease, disorder, or condition. As used herein, "alleviating" a disease, disorder, or condition means reducing the severity and / or frequency of occurrence of the symptoms of the disease, disorder, or condition.

[0034] The present invention discloses a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, the method comprising administering an anti-TRBV9 antibody using a defined dose and dosing regimen. The present invention also discloses the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, the anti-TRBV9 antibody being administered using a defined dose and dosing regimen.

[0035] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, the method comprising administering an anti-TRBV9 antibody at a dose of 0.03 to 10 mg / kg to a subject in need of treatment for the disease or disorder.

[0036] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, the method comprising administering an anti-TRBV9 antibody at a dose of 0.03 to 7 mg / kg to a subject in need of treatment for the disease or disorder.

[0037] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, the method comprising administering an anti-TRBV9 antibody at a dose of 0.3 to 7 mg / kg to a subject in need of treatment for the disease or disorder.

[0038] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, the method comprising administering an anti-TRBV9 antibody at a dose of 1 to 7 mg / kg to a subject in need of treatment for the disease or disorder.

[0039] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 2 to 7 mg / kg. In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 3 to 7 mg / kg.

[0040] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 4 to 7 mg / kg. In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 5 to 7 mg / kg.

[0041] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 6 to 7 mg / kg. In some embodiments of the invention, the anti-TRBV9 antibody is administered at a dose of 1 mg / kg, or 2 mg / kg, or 3 mg / kg, or 4 mg / kg, or 5 mg / kg, or 6 mg / kg, or 7 mg / kg.

[0042] In some embodiments of the invention, the anti-TRBV9 antibody is administered at a dose of 7.5 mg / kg, or 8 mg / kg, or 8.5 mg / kg, or 9 mg / kg, or 9.5 mg / kg, or 10 mg / kg.

[0043] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least every 3 to 12 months. In some embodiments of the present invention, the anti-TRBV9 antibody is administered every 3 to 12 months.

[0044] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least every 6 to 12 months. In some embodiments of the present invention, the anti-TRBV9 antibody is administered every 6 to 12 months.

[0045] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least every 3 months; or the anti-TRBV9 antibody is administered at least every 6 months; or the anti-TRBV9 antibody is administered at least every 9 months; or the anti-TRBV9 antibody is administered at least every 12 months.

[0046] In some embodiments of the present invention, the anti-TRBV9 antibody is administered every 3 months; or the anti-TRBV9 antibody is administered every 6 months; or the anti-TRBV9 antibody is administered every 9 months; or the anti-TRBV9 antibody is administered every 12 months.

[0047] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, the method comprising administering to a subject in need of treatment for the disease or disorder an anti-TRBV9 antibody at a dose of 75 to 675 mg.

[0048] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, the method comprising administering an anti-TRBV9 antibody at a dose of 100 to 650 mg to a subject in need of treatment for the disease or disorder.

[0049] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, the method comprising administering to a subject in need of treatment for the disease or disorder an anti-TRBV9 antibody at a dose of 75 to 175 mg; or 200 to 300 mg; or 325 to 425 mg; or 450 to 650 mg; or 575 to 675 mg.

[0050] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, the method comprising administering to a subject in need of treatment for the disease or disorder an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg; or 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg.

[0051] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 115 to 135 mg; or 240 to 260 mg; or 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg.

[0052] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 120 to 130 mg; or 245 to 255 mg; or 370 to 380 mg; or 495 to 505 mg; or 620 to 630 mg.

[0053] In some embodiments of the invention, the anti-TRBV9 antibody is administered at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg; or 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg.

[0054] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least every 3 to 12 months. In some embodiments of the present invention, the anti-TRBV9 antibody is administered every 3 to 12 months.

[0055] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least every 6 to 12 months. In some embodiments of the present invention, the anti-TRBV9 antibody is administered every 6 to 12 months.

[0056] In some embodiments of the invention, the anti-TRBV9 antibody is administered at least every 3 months; or at least every 6 months; or at least every 9 months; or at least every 12 months. In some embodiments of the invention, the anti-TRBV9 antibody is administered every 3 months; or every 6 months; or every 9 months; or every 12 months.

[0057] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising a first administration to a subject in need of treatment for the disease or disorder of an anti-TRBV9 antibody at a dose of 0.015 to 5 mg / kg, which is equivalent to half the main dose, of the anti-TRBV9 antibody, a second administration at least three months later of the anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg at least every six months.

[0058] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.015 to 5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration three months later at a main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody, and subsequent administration of the main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months.

[0059] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.015 to 5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration six months later at a main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody, and subsequent administration of the main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months.

[0060] In some embodiments of the invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.015 to 5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 9 months later of an anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg, and subsequent administrations of an anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg every 9 months; or every 12 months.

[0061] In some embodiments of the invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.015 to 5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 12 months later of the anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg every 12 months.

[0062] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising a first administration to a subject in need of treatment for the disease or disorder of an anti-TRBV9 antibody at a dose of 0.015 to 3.5 mg / kg, which is equivalent to half the main dose, of the anti-TRBV9 antibody, a second administration at least three months later of the anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg at least every six months.

[0063] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.015 to 3.5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration three months later of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg, and subsequent administration of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0064] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.015 to 3.5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration six months later of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg, and subsequent administration of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0065] In some embodiments of the invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.015 to 3.5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 9 months later of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg, and subsequent administration of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg every 9 months; or every 12 months.

[0066] In some embodiments of the invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.015 to 3.5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 12 months later of the anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg every 12 months.

[0067] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising a first administration to a subject in need of treatment for the disease or disorder of an anti-TRBV9 antibody at a dose of 0.15 to 5 mg / kg, which is equal to half the main dose, a second administration at least three months later of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg, and subsequent administrations of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg at least every six months.

[0068] In some embodiments of the present invention, the methods include a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.15 to 5 mg / kg, which is equal to half the main dose, a second administration three months later of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg, and subsequent administration of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0069] In some embodiments of the present invention, the methods include a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.15 to 5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration six months later of the anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0070] In some embodiments of the present invention, the methods include a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.15 to 5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 9 months later of the main dose of 0.3 to 10 mg / kg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg every 9 months; or every 12 months.

[0071] In some embodiments of the present invention, the methods include a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.15 to 5 mg / kg, which is equal to half the main dose, a second administration 12 months later of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg, and subsequent administrations of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg every 12 months.

[0072] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising a first administration to a subject in need of treatment for the disease or disorder of an anti-TRBV9 antibody at a dose of 0.15 to 3.5 mg / kg, which is equivalent to half the main dose, a second administration at least three months later of an anti-TRBV9 antibody at a main dose of 1 to 7 mg / kg, and subsequent administrations at least every six months of an anti-TRBV9 antibody at a main dose of 0.3 to 7 mg / kg.

[0073] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration three months later of an anti-TRBV9 antibody at a main dose of 1 to 7 mg / kg, and subsequent administration of an anti-TRBV9 antibody at a main dose of 0.3 to 7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0074] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration six months later of an anti-TRBV9 antibody at a main dose of 1 to 7 mg / kg, and subsequent administration of an anti-TRBV9 antibody at a main dose of 0.3 to 7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0075] In some embodiments of the invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 9 months later of an anti-TRBV9 antibody at a main dose of 1 to 7 mg / kg, and subsequent administration of an anti-TRBV9 antibody at a main dose of 0.3 to 7 mg / kg every 9 months; or every 12 months.

[0076] In some embodiments of the invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 12 months later of a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations every 12 months of a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody.

[0077] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising a first administration to a subject in need of treatment for the disease or disorder of an anti-TRBV9 antibody at a dose of 0.5 to 3.5 mg / kg, which is equivalent to half the main dose, a second administration at least three months later of an anti-TRBV9 antibody at a main dose of 1 to 7 mg / kg, and subsequent administrations of an anti-TRBV9 antibody at a main dose of 1 to 7 mg / kg at least every six months.

[0078] In some aspects, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising a first administration to a subject in need of treatment for the disease or disorder at a dose of 0.5 to 3.5 mg / kg, which is equivalent to half the main dose of an anti-TRBV9 antibody, a second administration three months later at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administration of the main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months.

[0079] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration six months later at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administration of the main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody every six months; or every nine months; or every 12 months.

[0080] In some embodiments of the invention, the method includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration 9 months later at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody every 9 months; or every 12 months.

[0081] In some embodiments of the invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 12 months later of an anti-TRBV9 antibody at a main dose of 1 to 7 mg / kg, and subsequent administrations of an anti-TRBV9 antibody at a main dose of 1 to 7 mg / kg every 12 months.

[0082] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration at least 3 months later of the anti-TRBV9 antibody at a dose of 1 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 1 mg / kg at least every 6 months.

[0083] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration three months later of the anti-TRBV9 antibody at a dose of 1 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 1 mg / kg every 6 months; or every 9 months; or every 12 months.

[0084] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration 6 months later of the anti-TRBV9 antibody at a dose of 1 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 1 mg / kg every 6 months; or every 9 months; or every 12 months.

[0085] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration 9 months later of the anti-TRBV9 antibody at a dose of 1 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 1 mg / kg every 9 months; or every 12 months.

[0086] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 1 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 1 mg / kg every 12 months.

[0087] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration at least 3 months later of the anti-TRBV9 antibody at a dose of 2 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 2 mg / kg at least every 6 months.

[0088] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration three months later of the anti-TRBV9 antibody at a dose of 2 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 2 mg / kg every six months; or every nine months; or every twelve months.

[0089] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration 6 months later of the anti-TRBV9 antibody at a dose of 2 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 2 mg / kg every 6 months; or every 9 months; or every 12 months.

[0090] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration 9 months later of the anti-TRBV9 antibody at a dose of 2 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 2 mg / kg every 9 months; or every 12 months.

[0091] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 2 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 2 mg / kg every 12 months.

[0092] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration at least 3 months later of the anti-TRBV9 antibody at a dose of 3 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 3 mg / kg at least every 6 months.

[0093] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration three months later of the anti-TRBV9 antibody at a dose of 3 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 3 mg / kg every 6 months; or every 9 months; or every 12 months.

[0094] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration 6 months later of the anti-TRBV9 antibody at a dose of 3 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 3 mg / kg every 6 months; or every 9 months; or every 12 months.

[0095] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration 9 months later of the anti-TRBV9 antibody at a dose of 3 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 3 mg / kg every 9 months; or every 12 months.

[0096] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 3 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 3 mg / kg every 12 months.

[0097] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration at least 3 months later of the anti-TRBV9 antibody at a dose of 4 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 4 mg / kg at least every 6 months.

[0098] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration three months later of the anti-TRBV9 antibody at a dose of 4 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 4 mg / kg every 6 months; or every 9 months; or every 12 months.

[0099] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration 6 months later of the anti-TRBV9 antibody at a dose of 4 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 4 mg / kg every 6 months; or every 9 months; or every 12 months.

[0100] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration 9 months later of the anti-TRBV9 antibody at a dose of 4 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 4 mg / kg every 9 months; or every 12 months.

[0101] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 4 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 4 mg / kg every 12 months.

[0102] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration at least 3 months later of the anti-TRBV9 antibody at a dose of 5 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 5 mg / kg at least every 6 months.

[0103] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration three months later of the anti-TRBV9 antibody at a dose of 5 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 5 mg / kg every six months; or every nine months; or every 12 months.

[0104] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration 6 months later of the anti-TRBV9 antibody at a dose of 5 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 5 mg / kg every 6 months; or every 9 months; or every 12 months.

[0105] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration 9 months later of the anti-TRBV9 antibody at a dose of 5 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 5 mg / kg every 9 months; or every 12 months.

[0106] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 5 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 5 mg / kg every 12 months.

[0107] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration at least 3 months later of the anti-TRBV9 antibody at a dose of 6 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 6 mg / kg at least every 6 months.

[0108] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration three months later of the anti-TRBV9 antibody at a dose of 6 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 6 mg / kg every 6 months; or every 9 months; or every 12 months.

[0109] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration 6 months later of the anti-TRBV9 antibody at a dose of 6 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 6 mg / kg every 6 months; or every 9 months; or every 12 months.

[0110] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration 9 months later of the anti-TRBV9 antibody at a dose of 6 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 6 mg / kg every 9 months; or every 12 months.

[0111] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 6 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 6 mg / kg every 12 months.

[0112] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg, a second administration at least 3 months later of the anti-TRBV9 antibody at a dose of 7 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 7 mg / kg at least every 6 months.

[0113] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg, a second administration three months later of the anti-TRBV9 antibody at a dose of 7 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0114] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg, a second administration 6 months later of the anti-TRBV9 antibody at a dose of 7 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0115] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg, a second administration 9 months later of the anti-TRBV9 antibody at a dose of 7 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 7 mg / kg every 9 months; or every 12 months.

[0116] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 7 mg / kg every 12 months.

[0117] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 8 mg / kg three months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 8 mg / kg every 6 months; or every 9 months; or every 12 months.

[0118] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration 6 months later of the anti-TRBV9 antibody at a dose of 8 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 8 mg / kg every 6 months; or every 9 months; or every 12 months.

[0119] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration 9 months later of the anti-TRBV9 antibody at a dose of 8 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 8 mg / kg every 9 months; or every 12 months.

[0120] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 8 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 8 mg / kg every 12 months.

[0121] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 9 mg / kg three months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 9 mg / kg every 6 months; or every 9 months; or every 12 months.

[0122] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration 6 months later of the anti-TRBV9 antibody at a dose of 9 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 9 mg / kg every 6 months; or every 9 months; or every 12 months.

[0123] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration 9 months later of the anti-TRBV9 antibody at a dose of 9 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 9 mg / kg every 9 months; or every 12 months.

[0124] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 9 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 9 mg / kg every 12 months.

[0125] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 10 mg / kg three months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0126] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration 6 months later of the anti-TRBV9 antibody at a dose of 10 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0127] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration 9 months later of the anti-TRBV9 antibody at a dose of 10 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 10 mg / kg every 9 months; or every 12 months.

[0128] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 10 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 10 mg / kg every 12 months.

[0129] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising a first administration of an anti-TRBV9 antibody at a dose of 75 to 300 mg to a subject in need of treatment for the disease or disorder, a second administration at least three months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 325 to 675 mg at least every six months.

[0130] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 75 to 300 mg to a subject in need of treatment for a disease or disorder, a second administration three months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, and subsequent administration of the main dose of 325 to 675 mg of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months.

[0131] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 75 to 300 mg to a subject in need of treatment for a disease or disorder, a second administration six months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, and subsequent administration of the main dose of 325 to 675 mg of the anti-TRBV9 antibody every six months; or every nine months; or every 12 months.

[0132] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 75 to 300 mg to a subject in need of treatment for a disease or disorder, a second administration 9 months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, and subsequent administration of the main dose of 325 to 675 mg of the anti-TRBV9 antibody every 9 months; or every 12 months.

[0133] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 75 to 300 mg to a subject in need of treatment for a disease or disorder, a second administration 12 months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 325 to 675 mg every 12 months.

[0134] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising a first administration of an anti-TRBV9 antibody at a dose of 100 to 275 mg to a subject in need of treatment for the disease or disorder, a second administration at least three months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 to 650 mg at least every six months.

[0135] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 100 to 275 mg to a subject in need of treatment for a disease or disorder, a second administration three months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, and subsequent administration of the main dose of 350 to 650 mg of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months.

[0136] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 100 to 275 mg to a subject in need of treatment for a disease or disorder, a second administration six months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, and subsequent administration of the main dose of 350 to 650 mg of the anti-TRBV9 antibody every six months; or every nine months; or every 12 months.

[0137] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 100 to 275 mg to a subject in need of treatment for a disease or disorder, a second administration 9 months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, and subsequent administration of the main dose of 350 to 650 mg of the anti-TRBV9 antibody every 9 months; or every 12 months.

[0138] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 100 to 275 mg to a subject in need of treatment for a disease or disorder, a second administration 12 months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 to 650 mg every 12 months.

[0139] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg to a subject in need of treatment for the disease or disorder, a second administration at least three months later of a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody at least every six months.

[0140] In some embodiments of the invention, the method includes: (i) administering to a subject in need of treatment for a disease or disorder a first administration of an anti-TRBV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration three months later of a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg of the anti-TRBV9 antibody, and subsequent administrations every six months of a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg of the anti-TRBV9 antibody; or (ii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration three months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every nine months at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (iii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration 3 months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (iv) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration six months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every six months at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (v) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration six months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every nine months at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (vi) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration 6 months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (vii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration 9 months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every 9 months at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (viii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration 9 months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (iх) A subject in need of treatment for a disease or disorder, comprising a first administration of an anti-TRBV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration 12 months later at a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg of an anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg of an anti-TRBV9 antibody. Includes.

[0141] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg to a subject in need of treatment for the disease or disorder, a second administration at least three months later of a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody at least every six months.

[0142] In some embodiments of the invention, the method includes: (i) administering to a subject in need of treatment for a disease or disorder a first administration of an anti-TRBV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration three months later of a main dose of 365-385 mg; or 490-510 mg; or 615-635 mg of the anti-TRBV9 antibody, and subsequent administrations every six months of a main dose of 365-385 mg; or 490-510 mg; or 615-635 mg of the anti-TRBV9 antibody; or (ii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration three months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every nine months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (iii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 3 months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (iv) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration six months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every six months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (v) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration six months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of an anti-TRBV9 antibody, and subsequent administrations every nine months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of an anti-TRBV9 antibody; or (vi) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 6 months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (vii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 9 months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 9 months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (viii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 9 months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (ix) A subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 12 months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody. Includes.

[0143] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need of treatment for the disease or disorder, a second administration at least three months later of a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody at least every six months.

[0144] In some aspects, the present invention provides a method of treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising: (i) administering to a subject in need of treatment for the disease or disorder a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration three months later of a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every six months of a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; or (ii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration 3 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every 9 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; or (iii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration 3 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; or (iv) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration six months later of a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every six months of a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; or (v) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration 6 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every 9 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; or (vi) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration 6 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; or (vii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration 9 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every 9 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; or (viii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration 9 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; or (ix) A method comprising administering to a subject in need of treatment for a disease or disorder a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration 12 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody.

[0145] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration at least three months later of an anti-TRBV9 antibody at a dose of 370 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 370 mg at least every six months.

[0146] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration three months later of an anti-TRBV9 antibody at a dose of 370 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 370 mg every six months; or every nine months; or every 12 months.

[0147] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration 6 months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 370 mg every 6 months; or every 9 months; or every 12 months.

[0148] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration 9 months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 370 mg every 9 months; or every 12 months.

[0149] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration 12 months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 12 months.

[0150] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration at least three months later of an anti-TRBV9 antibody at a dose of 375 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 375 mg at least every six months.

[0151] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration three months later of an anti-TRBV9 antibody at a dose of 375 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 375 mg every six months; or every nine months; or every 12 months.

[0152] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration 6 months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 375 mg every 6 months; or every 9 months; or every 12 months.

[0153] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration 9 months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 375 mg every 9 months; or every 12 months.

[0154] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration 12 months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 12 months.

[0155] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration at least three months later of an anti-TRBV9 antibody at a dose of 380 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 380 mg at least every six months.

[0156] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration three months later of an anti-TRBV9 antibody at a dose of 380 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 380 mg every six months; or every nine months; or every 12 months.

[0157] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration 6 months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 380 mg every 6 months; or every 9 months; or every 12 months.

[0158] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration 9 months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 380 mg every 9 months; or every 12 months.

[0159] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration 12 months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0160] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, based on a subject's body weight of 30 to 50 kg, a second administration at least three months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg at least every six months.

[0161] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, based on a subject's body weight of 30 to 50 kg, a second administration three months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 370 mg every six months; or every nine months; or every 12 months.

[0162] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, based on a subject's body weight of 30 to 50 kg, a second administration six months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 370 mg every six months; or every nine months; or every 12 months.

[0163] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, based on a subject's body weight of 30 to 50 kg, a second administration 9 months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 370 mg every 9 months; or every 12 months.

[0164] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, based on a subject's body weight of 30 to 50 kg, a second administration 12 months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 12 months.

[0165] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, based on a subject's body weight of 30 to 50 kg, a second administration at least three months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg at least every six months.

[0166] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, based on a subject's body weight of 30 to 50 kg, a second administration three months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 375 mg every six months; or every nine months; or every 12 months.

[0167] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, based on a subject's body weight of 30 to 50 kg, a second administration six months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 375 mg every six months; or every nine months; or every 12 months.

[0168] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, based on a subject's body weight of 30 to 50 kg, a second administration 9 months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 375 mg every 9 months; or every 12 months.

[0169] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, based on a subject's body weight of 30 to 50 kg, a second administration 12 months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 12 months.

[0170] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, based on a subject's body weight of 30 to 50 kg, a second administration at least three months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg at least every six months.

[0171] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, based on a subject's body weight of 30 to 50 kg, a second administration three months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 380 mg every six months; or every nine months; or every 12 months.

[0172] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, based on a subject's body weight of 30 to 50 kg, a second administration six months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 380 mg every six months; or every nine months; or every 12 months.

[0173] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, based on a subject's body weight of 30 to 50 kg, a second administration 9 months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 380 mg every 9 months; or every 12 months.

[0174] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, based on a subject's body weight of 30 to 50 kg, a second administration 12 months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0175] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration at least three months later of an anti-TRBV9 antibody at a dose of 495 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 495 mg at least every six months.

[0176] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration three months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 495 mg every six months; or every nine months; or every 12 months.

[0177] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration six months later of an anti-TRBV9 antibody at a dose of 495 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 495 mg every six months; or every nine months; or every 12 months.

[0178] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 9 months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 495 mg every 9 months; or every 12 months.

[0179] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 12 months later of an anti-TRBV9 antibody at a dose of 495 mg, and subsequent administrations of an anti-TRBV9 antibody at a dose of 495 mg every 12 months.

[0180] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration at least three months later of an anti-TRBV9 antibody at a dose of 500 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 500 mg at least every six months.

[0181] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration three months later of an anti-TRBV9 antibody at a dose of 500 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 500 mg every six months; or every nine months; or every 12 months.

[0182] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration six months later of an anti-TRBV9 antibody at a dose of 500 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 500 mg every six months; or every nine months; or every 12 months.

[0183] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 9 months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 500 mg every 9 months; or every 12 months.

[0184] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 12 months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg every 12 months.

[0185] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration at least three months later of an anti-TRBV9 antibody at a dose of 505 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 505 mg at least every six months.

[0186] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration three months later of an anti-TRBV9 antibody at a dose of 505 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 505 mg every six months; or every nine months; or every 12 months.

[0187] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration six months later of an anti-TRBV9 antibody at a dose of 505 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 505 mg every six months; or every nine months; or every 12 months.

[0188] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 9 months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 505 mg every 9 months; or every 12 months.

[0189] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 12 months later of an anti-TRBV9 antibody at a dose of 505 mg, and subsequent administrations of an anti-TRBV9 antibody at a dose of 505 mg every 12 months.

[0190] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 51 to 89 kg, a second administration at least three months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg at least every six months.

[0191] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 51 to 89 kg, a second administration three months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 495 mg every six months; or every nine months; or every 12 months.

[0192] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 51 to 89 kg, a second administration six months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 495 mg every six months; or every nine months; or every 12 months.

[0193] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 51 to 89 kg, a second administration 9 months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 495 mg every 9 months; or every 12 months.

[0194] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 12 months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg every 12 months, based on a subject's body weight of 51 to 89 kg.

[0195] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 51 to 89 kg, a second administration at least three months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg at least every six months.

[0196] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 51 to 89 kg, a second administration three months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 500 mg every six months; or every nine months; or every 12 months.

[0197] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 51 to 89 kg, a second administration six months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 500 mg every six months; or every nine months; or every 12 months.

[0198] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 51 to 89 kg, a second administration 9 months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 500 mg every 9 months; or every 12 months.

[0199] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 12 months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 500 mg every 12 months, based on a subject's body weight of 51 to 89 kg.

[0200] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 51 to 89 kg, a second administration at least three months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg at least every six months.

[0201] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 51 to 89 kg, a second administration three months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 505 mg every six months; or every nine months; or every 12 months.

[0202] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 51 to 89 kg, a second administration six months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 505 mg every six months; or every nine months; or every 12 months.

[0203] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 51 to 89 kg, a second administration 9 months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 505 mg every 9 months; or every 12 months.

[0204] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 12 months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg every 12 months, based on a subject's body weight of 51 to 89 kg.

[0205] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration at least three months later of an anti-TRBV9 antibody at a dose of 620 mg, and subsequent administrations of an anti-TRBV9 antibody at a dose of 620 mg at least every six months.

[0206] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration three months later of an anti-TRBV9 antibody at a dose of 620 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 620 mg every six months; or every nine months; or every 12 months.

[0207] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration six months later of an anti-TRBV9 antibody at a dose of 620 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 620 mg every six months; or every nine months; or every 12 months.

[0208] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 9 months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 620 mg every 9 months; or every 12 months.

[0209] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 12 months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0210] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration at least three months later of an anti-TRBV9 antibody at a dose of 625 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 625 mg at least every six months.

[0211] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration three months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 625 mg every six months; or every nine months; or every 12 months.

[0212] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration six months later of an anti-TRBV9 antibody at a dose of 625 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 625 mg every six months; or every nine months; or every 12 months.

[0213] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 9 months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 625 mg every 9 months; or every 12 months.

[0214] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 12 months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0215] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration at least three months later of an anti-TRBV9 antibody at a dose of 630 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 630 mg at least every six months.

[0216] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration three months later of an anti-TRBV9 antibody at a dose of 630 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 630 mg every six months; or every nine months; or every 12 months.

[0217] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration six months later of an anti-TRBV9 antibody at a dose of 630 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 630 mg every six months; or every nine months; or every 12 months.

[0218] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 9 months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 630 mg every 9 months; or every 12 months.

[0219] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 12 months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0220] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 90 to 150 kg, a second administration at least three months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg at least every six months.

[0221] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 90 to 150 kg, a second administration three months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 620 mg every six months; or every nine months; or every 12 months.

[0222] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 90 to 150 kg, a second administration six months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 620 mg every six months; or every nine months; or every 12 months.

[0223] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 90 to 150 kg, a second administration 9 months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 620 mg every 9 months; or every 12 months.

[0224] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 90 to 150 kg, a second administration 12 months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0225] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 90 to 150 kg, a second administration at least three months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg at least every six months.

[0226] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 90 to 150 kg, a second administration three months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 625 mg every six months; or every nine months; or every 12 months.

[0227] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 90 to 150 kg, a second administration six months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 625 mg every six months; or every nine months; or every 12 months.

[0228] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 90 to 150 kg, a second administration 9 months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 625 mg every 9 months; or every 12 months.

[0229] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 90 to 150 kg, a second administration 12 months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0230] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 90 to 150 kg, a second administration at least three months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg at least every six months.

[0231] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 90 to 150 kg, a second administration three months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 630 mg every six months; or every nine months; or every 12 months.

[0232] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 90 to 150 kg, a second administration six months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 630 mg every six months; or every nine months; or every 12 months.

[0233] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 90 to 150 kg, a second administration 9 months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 9 months; or every 12 months.

[0234] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 90 to 150 kg, a second administration 12 months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0235] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising: a first administration to a subject in need of treatment for the disease or disorder at a dose of 0.015 to 5 mg / kg, which is equal to half the main dose of an anti-TRBV9 antibody; a second administration at least 3 months later at a main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody; a third administration at least 6 months later at a main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody; and subsequent administrations at least every 12 months at a main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody.

[0236] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.015 to 5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration three months later of an anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg, a third administration six or nine months later of an anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg; or a third administration 12 months later of an anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg, and subsequent administrations every 12 months of an anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg.

[0237] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.015 to 5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 6 months later of an anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg, a third administration 6 or 9 months later of an anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg; or a third administration 12 months later of an anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg, and subsequent administrations every 12 months of an anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg.

[0238] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.015 to 5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 9 months later of an anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg, a third administration 9 months later of an anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg; or a third administration 12 months later of an anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg, and subsequent administrations of an anti-TRBV9 antibody at a main dose of 0.03 to 10 mg / kg every 12 months.

[0239] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.015 to 5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration 12 months later at a main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody, a third administration 12 months later at a main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody.

[0240] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising: a first administration to a subject in need of treatment for the disease or disorder at a dose of 0.015 to 3.5 mg / kg, which is equal to half the main dose of an anti-TRBV9 antibody; a second administration at least 3 months later at a main dose of 0.03 to 7 mg / kg of the anti-TRBV9 antibody; a third administration at least 6 months later at a main dose of 0.03 to 7 mg / kg of the anti-TRBV9 antibody; and subsequent administrations at least every 12 months at a main dose of 0.03 to 7 mg / kg of the anti-TRBV9 antibody.

[0241] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.015 to 3.5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration three months later of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg, a third administration six or nine months later of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg; or a third administration 12 months later of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg, and subsequent administrations every 12 months of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg.

[0242] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.015 to 3.5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 6 months later of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg, a third administration 6 or 9 months later of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg; or a third administration 12 months later of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg, and subsequent administrations every 12 months of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg.

[0243] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.015 to 3.5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 9 months later of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg, a third administration 9 months later of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg; or a third administration 12 months later of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg, and subsequent administrations of an anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg every 12 months.

[0244] In some embodiments of the invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.015 to 3.5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 12 months later of the anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg, a third administration 12 months later of the anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 0.03 to 7 mg / kg every 12 months.

[0245] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising: a first administration to a subject in need of treatment for the disease or disorder at a dose of 0.15 to 5 mg / kg, which is equal to half the main dose of an anti-TRBV9 antibody; a second administration at least 3 months later at a main dose of 0.3 to 10 mg / kg of the anti-TRBV9 antibody; a third administration at least 6 months later at a main dose of 0.3 to 10 mg / kg of the anti-TRBV9 antibody; and subsequent administrations at least every 12 months at a main dose of 0.3 to 10 mg / kg of the anti-TRBV9 antibody.

[0246] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.15 to 5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration three months later of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg, a third administration six or nine months later of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg; or a third administration 12 months later of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg, and subsequent administrations every 12 months of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg.

[0247] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.15 to 5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 6 months later of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg, a third administration 6 or 9 months later of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg; or a third administration 12 months later of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg, and subsequent administrations every 12 months of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg.

[0248] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.15 to 5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 9 months later of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg, a third administration 9 months later of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg; or a third administration 12 months later of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg, and subsequent administrations of an anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg every 12 months.

[0249] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.15 to 5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 12 months later of the anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg, a third administration 12 months later of the anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 0.3 to 10 mg / kg every 12 months.

[0250] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising: a first administration to a subject in need of treatment for the disease or disorder at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose of an anti-TRBV9 antibody; a second administration at least 3 months later at a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody; a third administration at least 6 months later at a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody; and subsequent administrations at least every 12 months at a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody.

[0251] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration three months later at a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody, a third administration six months later; or nine months later; or 12 months later at a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody.

[0252] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration 6 months later at a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody.

[0253] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration 9 months later at a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody, a third administration 9 months later at a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody; or a third administration 12 months later at a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody.

[0254] In some embodiments of the invention, the method includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration 12 months later at a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody, a third administration 12 months later at a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 0.3 to 7 mg / kg of the anti-TRBV9 antibody.

[0255] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising: a first administration to a subject in need of treatment for the disease or disorder of an anti-TRBV9 antibody at a dose of 0.5 to 3.5 mg / kg, which is equivalent to half the main dose; a second administration at least 3 months later of an anti-TRBV9 antibody at a main dose of 1 to 7 mg / kg; a third administration at least 6 months later of an anti-TRBV9 antibody at a main dose of 1 to 7 mg / kg; and subsequent administrations of an anti-TRBV9 antibody at a main dose of 1 to 7 mg / kg at least every 12 months.

[0256] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising: a first administration to a subject in need of treatment for the disease or disorder at a dose of 0.5 to 3.5 mg / kg, which is equivalent to half the main dose of an anti-TRBV9 antibody; a second administration three months later at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody; a third administration six months, or nine months, or twelve months later at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody; and subsequent administrations every 12 months at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody.

[0257] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.5 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration 6 months later at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody.

[0258] In some embodiments of the present invention, the method includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.5 to 3.5 mg / kg, which is equal to half the main dose of an anti-TRBV9 antibody, a second administration 9 months later at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody, a third administration 9 months later at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody; or a third administration 12 months later at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody.

[0259] In some embodiments of the invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 0.5 to 3.5 mg / kg, which is equal to half the main dose, of the anti-TRBV9 antibody, a second administration 12 months later of a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody, a third administration 12 months later of a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 1 to 7 mg / kg every 12 months.

[0260] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration at least 3 months later of the anti-TRBV9 antibody at a dose of 1 mg / kg, a third administration at least 6 months later of the anti-TRBV9 antibody at a dose of 1 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 1 mg / kg at least every 12 months.

[0261] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 1 mg / kg three months later, a third administration of the anti-TRBV9 antibody at a dose of 1 mg / kg six months later; or nine months later; or 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 1 mg / kg every 12 months.

[0262] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 1 mg / kg 6 months later, a third administration of the anti-TRBV9 antibody at a dose of 1 mg / kg 6 months later; or 9 months later; or 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 1 mg / kg every 12 months.

[0263] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration 9 months later of an anti-TRBV9 antibody at a dose of 1 mg / kg, a third administration 9 months later of an anti-TRBV9 antibody at a dose of 1 mg / kg; or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 1 mg / kg every 12 months.

[0264] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 1 mg / kg, a third administration 12 months later of the anti-TRBV9 antibody at a dose of 1 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 1 mg / kg every 12 months.

[0265] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration at least 3 months later of the anti-TRBV9 antibody at a dose of 2 mg / kg, a third administration at least 6 months later of the anti-TRBV9 antibody at a dose of 2 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 2 mg / kg at least every 12 months.

[0266] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 2 mg / kg three months later, a third administration of the anti-TRBV9 antibody at a dose of 2 mg / kg six months later; or nine months later; or 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 2 mg / kg every 12 months.

[0267] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 2 mg / kg 6 months later, a third administration of the anti-TRBV9 antibody at a dose of 2 mg / kg 6 months later; or 9 months later; or 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 2 mg / kg every 12 months.

[0268] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration 9 months later of the anti-TRBV9 antibody at a dose of 2 mg / kg, a third administration 9 months later of the anti-TRBV9 antibody at a dose of 2 mg / kg; or a third administration 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 2 mg / kg every 12 months.

[0269] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 2 mg / kg, a third administration 12 months later of the anti-TRBV9 antibody at a dose of 2 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 2 mg / kg every 12 months.

[0270] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration at least 3 months later of the anti-TRBV9 antibody at a dose of 3 mg / kg, a third administration at least 6 months later of the anti-TRBV9 antibody at a dose of 3 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 3 mg / kg at least every 12 months.

[0271] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 3 mg / kg three months later, a third administration of the anti-TRBV9 antibody at a dose of 3 mg / kg six months later; or nine months later; or 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 3 mg / kg every 12 months.

[0272] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 3 mg / kg 6 months later, a third administration of the anti-TRBV9 antibody at a dose of 3 mg / kg 6 months later; or 9 months later; or 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 3 mg / kg every 12 months.

[0273] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration 9 months later at a dose of 3 mg / kg of the anti-TRBV9 antibody, a third administration 9 months later at a dose of 3 mg / kg of the anti-TRBV9 antibody; or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 3 mg / kg every 12 months.

[0274] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 3 mg / kg, a third administration 12 months later of the anti-TRBV9 antibody at a dose of 3 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 3 mg / kg every 12 months.

[0275] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration at least 3 months later of the anti-TRBV9 antibody at a dose of 4 mg / kg, a third administration at least 6 months later of the anti-TRBV9 antibody at a dose of 4 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 4 mg / kg at least every 12 months.

[0276] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 4 mg / kg three months later, a third administration of the anti-TRBV9 antibody at a dose of 4 mg / kg six months later; or nine months later; or 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 4 mg / kg every 12 months.

[0277] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 4 mg / kg 6 months later, a third administration of the anti-TRBV9 antibody at a dose of 4 mg / kg 6 months later; or 9 months later; or 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 4 mg / kg every 12 months.

[0278] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration 9 months later at a dose of 4 mg / kg of the anti-TRBV9 antibody, a third administration 9 months later at a dose of 4 mg / kg of the anti-TRBV9 antibody; or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 4 mg / kg every 12 months.

[0279] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 4 mg / kg, a third administration 12 months later of the anti-TRBV9 antibody at a dose of 4 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 4 mg / kg every 12 months.

[0280] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration at least 3 months later of the anti-TRBV9 antibody at a dose of 5 mg / kg, a third administration at least 6 months later of the anti-TRBV9 antibody at a dose of 5 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 5 mg / kg at least every 12 months.

[0281] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 5 mg / kg three months later, a third administration of the anti-TRBV9 antibody at a dose of 5 mg / kg six months later; or nine months later; or 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 5 mg / kg every 12 months.

[0282] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 5 mg / kg 6 months later, a third administration of the anti-TRBV9 antibody at a dose of 5 mg / kg 6 months later; or 9 months later; or 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 5 mg / kg every 12 months.

[0283] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration 9 months later of the anti-TRBV9 antibody at a dose of 5 mg / kg, a third administration 9 months later of the anti-TRBV9 antibody at a dose of 5 mg / kg; or a third administration 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 5 mg / kg every 12 months.

[0284] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 5 mg / kg 12 months later, a third administration of the anti-TRBV9 antibody at a dose of 5 mg / kg 6 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 5 mg / kg every 12 months.

[0285] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration at least 3 months later of the anti-TRBV9 antibody at a dose of 6 mg / kg, a third administration at least 6 months later of the anti-TRBV9 antibody at a dose of 6 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 6 mg / kg at least every 12 months.

[0286] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 6 mg / kg three months later, a third administration of the anti-TRBV9 antibody at a dose of 6 mg / kg six months later; or nine months later; or 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 6 mg / kg every 12 months.

[0287] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 6 mg / kg 6 months later, a third administration of the anti-TRBV9 antibody at a dose of 6 mg / kg 6 months later; or 9 months later; or 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 6 mg / kg every 12 months.

[0288] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration 9 months later at a dose of 6 mg / kg of the anti-TRBV9 antibody, a third administration 9 months later at a dose of 6 mg / kg of the anti-TRBV9 antibody; or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 6 mg / kg every 12 months.

[0289] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 6 mg / kg, a third administration 12 months later of the anti-TRBV9 antibody at a dose of 6 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 6 mg / kg every 12 months.

[0290] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg to a subject in need of treatment for a disease or disorder, a second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg at least 3 months later, a third administration of the anti-TRBV9 antibody at a dose of 7 mg / kg at least 6 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 7 mg / kg at least every 12 months.

[0291] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg to a subject in need of treatment for a disease or disorder, a second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg three months later, a third administration of the anti-TRBV9 antibody at a dose of 7 mg / kg six months later; or nine months later; or 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 7 mg / kg every 12 months.

[0292] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg to a subject in need of treatment for a disease or disorder, a second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg 6 months later, a third administration of the anti-TRBV9 antibody at a dose of 7 mg / kg 6 months later; or 9 months later; or 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 7 mg / kg every 12 months.

[0293] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg to a subject in need of treatment for a disease or disorder, a second administration 9 months later at a dose of 7 mg / kg of the anti-TRBV9 antibody, a third administration 9 months later at a dose of 7 mg / kg of the anti-TRBV9 antibody; or a third administration 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 7 mg / kg every 12 months.

[0294] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg to a subject in need of treatment for a disease or disorder, a second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg 12 months later, a third administration of the anti-TRBV9 antibody at a dose of 7 mg / kg 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 7 mg / kg every 12 months.

[0295] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 8 mg / kg three months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 8 mg / kg every 6 months; or every 9 months; or every 12 months.

[0296] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration 6 months later of the anti-TRBV9 antibody at a dose of 8 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 8 mg / kg every 6 months; or every 9 months; or every 12 months.

[0297] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration 9 months later of the anti-TRBV9 antibody at a dose of 8 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 8 mg / kg every 9 months; or every 12 months.

[0298] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 8 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 8 mg / kg every 12 months.

[0299] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 9 mg / kg three months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 9 mg / kg every 6 months; or every 9 months; or every 12 months.

[0300] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration 6 months later of the anti-TRBV9 antibody at a dose of 9 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 9 mg / kg every 6 months; or every 9 months; or every 12 months.

[0301] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration 9 months later of the anti-TRBV9 antibody at a dose of 9 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 9 mg / kg every 9 months; or every 12 months.

[0302] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 9 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 9 mg / kg every 12 months.

[0303] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 10 mg / kg three months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0304] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration 6 months later of the anti-TRBV9 antibody at a dose of 10 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0305] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration 9 months later of the anti-TRBV9 antibody at a dose of 10 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 10 mg / kg every 9 months; or every 12 months.

[0306] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 10 mg / kg, and subsequent administration of the anti-TRBV9 antibody at a dose of 10 mg / kg every 12 months.

[0307] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising a first administration of an anti-TRBV9 antibody at a dose of 75 to 300 mg to a subject in need of treatment for the disease or disorder, a second administration at least 3 months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, a third administration at least 6 months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 325 to 675 mg of the anti-TRBV9 antibody at least every 12 months.

[0308] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 75 to 300 mg to a subject in need of treatment for a disease or disorder, a second administration three months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, a third administration six months later; or nine months later; or 12 months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months of a main dose of 325 to 675 mg of the anti-TRBV9 antibody.

[0309] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 75 to 300 mg to a subject in need of treatment for a disease or disorder, a second administration 6 months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 325 to 675 mg every 12 months.

[0310] In some embodiments of the invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 75 to 300 mg, a second administration 9 months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, a third administration 9 months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody; or a third administration 12 months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months of a main dose of 325 to 675 mg of the anti-TRBV9 antibody.

[0311] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 75 to 300 mg to a subject in need of treatment for a disease or disorder, a second administration 12 months later at a main dose of 325 to 675 mg of the anti-TRBV9 antibody, a third administration 12 months later at a main dose of 325 to 675 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 325 to 675 mg of the anti-TRBV9 antibody.

[0312] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising: a first administration of an anti-TRBV9 antibody at a dose of 100 to 275 mg, a second administration at least 3 months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, a third administration at least 6 months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 350 to 650 mg of the anti-TRBV9 antibody at least every 12 months to a subject in need of treatment for the disease or disorder.

[0313] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 100 to 275 mg to a subject in need of treatment for a disease or disorder, a second administration three months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, a third administration six months later; or nine months later; or 12 months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months of a main dose of 350 to 650 mg of the anti-TRBV9 antibody.

[0314] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 100 to 275 mg to a subject in need of treatment for a disease or disorder, a second administration 6 months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, a third administration 6 months; 9 months; or 12 months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 to 650 mg every 12 months.

[0315] In some embodiments of the invention, the method includes a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 100 to 275 mg, a second administration 9 months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, a third administration 9 months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody; or a third administration 12 months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months of a main dose of 350 to 650 mg of the anti-TRBV9 antibody.

[0316] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 100 to 275 mg to a subject in need of treatment for a disease or disorder, a second administration 12 months later at a main dose of 350 to 650 mg of the anti-TRBV9 antibody, a third administration 12 months later at a main dose of 350 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 350 to 650 mg of the anti-TRBV9 antibody.

[0317] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising: a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg; a second administration at least 3 months later of a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody; a third administration at least 6 months later of a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody; and subsequent administrations of the main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody at least every 12 months to a subject in need of treatment for the disease or disorder.

[0318] In some embodiments of the invention, the method includes (i) administering to a subject in need of treatment for a disease or disorder a first administration of an anti-TRBV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration three months later with a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg of the anti-TRBV9 antibody, a third administration six months later with a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months with a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg of the anti-TRBV9 antibody; or (ii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration 3 months later with a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody, a third administration 9 months later with a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months with a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody; or (iii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration 3 months later of a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, a third administration 12 months later of a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every 12 months of a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (iv) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration 6 months later of a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, a third administration 6 months later of a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every 12 months of a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (v) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration 6 months later with a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody, a third administration 9 months later with a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months with a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody; or (vi) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration 6 months later with a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody, a third administration 12 months later with a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months with a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody; or (vii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration 9 months later of a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, a third administration 9 months later of a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every 12 months of a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (viii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration 9 months later with a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody, a third administration 12 months later with a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months with a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody; or (ix) to a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration 12 months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody, a third administration 12 months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody. Includes.

[0319] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising: a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg; a second administration at least 3 months later of a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; a third administration at least 6 months later of a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; and subsequent administrations of the main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody at least every 12 months to a subject in need of treatment for the disease or disorder.

[0320] In some embodiments of the invention, the method includes: (i) administering to a subject in need of treatment for a disease or disorder a first administration of an anti-TRBV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration three months later with a main dose of 365-385 mg; or 490-510 mg; or 615-635 mg of the anti-TRBV9 antibody, a third administration six months later with a main dose of 365-385 mg; or 490-510 mg; or 615-635 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months with a main dose of 365-385 mg; or 490-510 mg; or 615-635 mg of the anti-TRBV9 antibody; or (ii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 3 months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, a third administration 9 months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (iii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 3 months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, a third administration 12 months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (iv) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 6 months later of a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of an anti-TRBV9 antibody, a third administration 6 months later of a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of an anti-TRBV9 antibody, and subsequent administrations every 12 months of a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of an anti-TRBV9 antibody; or (v) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 6 months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, a third administration 9 months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (vi) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 6 months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, a third administration 12 months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (vii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 9 months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, a third administration 9 months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (viii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 9 months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, a third administration 12 months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (ix) to a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 12 months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, a third administration 12 months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody. Includes.

[0321] In one aspect, the invention provides a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising administering to a subject in need of treatment for the disease or disorder a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, and a second administration of an anti-TRBV9 antibody at a dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg. or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; and subsequent administrations of the anti-TRBV9 antibody at least every 12 months with a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody.

[0322] In one aspect, the invention provides a method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising: (i) a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need of treatment for the disease or disorder; and (ii) a second administration of an anti-TRBV9 antibody at a dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg. or 630 mg main dose, a second dose 3 months later, a third dose 6 months later of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg main dose of the anti-TRBV9 antibody, and subsequent doses every 12 months of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg main dose of the anti-TRBV9 antibody, or (ii) a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need of treatment for a disease or disorder, followed three months later by a second administration of an anti-TRBV9 antibody at a primary dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg; or 620 mg; or 625 mg; or 630 mg main dose, and subsequent administrations of an anti-TRBV9 antibody every 12 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg; or (iii) a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need of treatment for a disease or disorder, followed three months later by a second administration of an anti-TRBV9 antibody at a primary dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg; or 620 mg; or 625 mg; or 630 mg main dose, and subsequent administrations of an anti-TRBV9 antibody every 12 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg; or (iv) A subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, followed six months later by a second administration of an anti-TRBV9 antibody at a primary dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg, or 620 mg; or 625 mg; or 630 mg main dose, followed by a third dose 6 months later, and subsequent doses of an anti-TRBV9 antibody every 12 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg; or (v) A subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, followed six months later by a second administration of an anti-TRBV9 antibody at a primary dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg, or 620 mg; or 625 mg; or 630 mg main dose, and subsequent administrations of an anti-TRBV9 antibody every 12 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg; or (vi) A subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, followed six months later by a second administration of an anti-TRBV9 antibody at a primary dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg, or 620 mg; or 625 mg; or 630 mg main dose, and subsequent administrations of an anti-TRBV9 antibody every 12 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg; or (vii) a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need of treatment for a disease or disorder, followed 9 months later by a second administration of an anti-TRBV9 antibody at a primary dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg; an anti-TRBV9 antibody or 620 mg; or 625 mg; or 630 mg main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of anti-TRBV9 antibody administered 9 months later, and subsequent administrations of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of anti-TRBV9 antibody administered every 12 months; or (viii) A subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, followed 9 months later by a second administration of an anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg, an anti-TRBV9 antibody or 620 mg; or 625 mg; or 630 mg of the main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody every 12 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg; (iх) A first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need of treatment for a disease or disorder, followed by a second administration 12 months later at a primary dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of an anti-TRBV9 antibody; a third dose 12 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the antibody, and subsequent doses of the anti-TRBV9 antibody every 12 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg The present invention relates to a method comprising:

[0323] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration at least 3 months later at a dose of 370 mg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg at least every 12 months.

[0324] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration of an anti-TRBV9 antibody at a dose of 370 mg three months later, a third administration of an anti-TRBV9 antibody at a dose of 370 mg six months later; or nine months later; or 12 months later, and subsequent administration of an anti-TRBV9 antibody at a dose of 370 mg every 12 months.

[0325] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration 6 months later at a dose of 370 mg of the anti-TRBV9 antibody, a third administration 6 months or 9 months later at a dose of 370 mg of the anti-TRBV9 antibody; or a third administration 12 months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 12 months.

[0326] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration 9 months later at a dose of 370 mg of the anti-TRBV9 antibody, a third administration 9 months later at a dose of 370 mg of the anti-TRBV9 antibody; or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 370 mg every 12 months.

[0327] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 370 mg, a third administration 12 months later of the anti-TRBV9 antibody at a dose of 370 mg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 12 months.

[0328] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration at least 3 months later at a dose of 375 mg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg at least every 12 months.

[0329] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration of an anti-TRBV9 antibody at a dose of 375 mg three months later, a third administration of an anti-TRBV9 antibody at a dose of 375 mg six months later; or nine months later; or 12 months later, and subsequent administration of an anti-TRBV9 antibody at a dose of 375 mg every 12 months.

[0330] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration 6 months later at a dose of 375 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 375 mg every 12 months.

[0331] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration 9 months later at a dose of 375 mg of the anti-TRBV9 antibody, a third administration 9 months later at a dose of 375 mg of the anti-TRBV9 antibody; or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 375 mg every 12 months.

[0332] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 375 mg, a third administration 12 months later of the anti-TRBV9 antibody at a dose of 375 mg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 12 months.

[0333] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration at least 3 months later at a dose of 380 mg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg at least every 12 months.

[0334] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration of an anti-TRBV9 antibody at a dose of 380 mg three months later, a third administration of an anti-TRBV9 antibody at a dose of 380 mg six months later; or nine months later; or 12 months later, and subsequent administration of an anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0335] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration 6 months later at a dose of 380 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0336] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration 9 months later at a dose of 380 mg of the anti-TRBV9 antibody, a third administration 9 months later at a dose of 380 mg of the anti-TRBV9 antibody; or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0337] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 380 mg, a third administration 12 months later of the anti-TRBV9 antibody at a dose of 380 mg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0338] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, based on a subject's body weight of 30 to 50 kg, a second administration at least 3 months later at a dose of 370 mg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg at least every 12 months.

[0339] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, based on a subject's body weight of 30 to 50 kg, a second administration three months later at a dose of 370 mg of the anti-TRBV9 antibody, a third administration six months later; or nine months later; or 12 months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 12 months.

[0340] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, based on a subject's body weight of 30 to 50 kg, a second administration 6 months later at a dose of 370 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 12 months.

[0341] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, based on a subject's body weight of 30 to 50 kg, a second administration 9 months later at a dose of 370 mg, a third administration 9 months later at a dose of 370 mg, or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 370 mg every 12 months.

[0342] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration 12 months later at a dose of 370 mg of the anti-TRBV9 antibody, a third administration 12 months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 12 months, based on a subject's body weight of 30 to 50 kg.

[0343] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, based on a subject's body weight of 30 to 50 kg, a second administration at least 3 months later at a dose of 375 mg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg at least every 12 months.

[0344] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, based on a subject's body weight of 30 to 50 kg, a second administration three months later at a dose of 375 mg of the anti-TRBV9 antibody, a third administration six months later; or nine months later; or 12 months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 12 months.

[0345] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, based on a subject's body weight of 30 to 50 kg, a second administration 6 months later at a dose of 375 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 12 months.

[0346] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, based on a subject's body weight of 30 to 50 kg, a second administration 9 months later at a dose of 375 mg of the anti-TRBV9 antibody, a third administration 9 or 12 months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 12 months.

[0347] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration 12 months later at a dose of 375 mg of the anti-TRBV9 antibody, a third administration 12 months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 12 months, based on a subject's body weight of 30 to 50 kg.

[0348] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, based on a subject's body weight of 30 to 50 kg, a second administration at least 3 months later at a dose of 380 mg, a third administration at least 6 months later at a dose of 380 mg, and subsequent administrations of an anti-TRBV9 antibody at a dose of 380 mg at least every 12 months.

[0349] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, based on a subject's body weight of 30 to 50 kg, a second administration three months later at a dose of 380 mg of the anti-TRBV9 antibody, a third administration six months later; or nine months later; or 12 months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0350] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, based on a subject's body weight of 30 to 50 kg, a second administration 6 months later at a dose of 380 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0351] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, based on a subject's body weight of 30 to 50 kg, a second administration 9 months later at a dose of 380 mg, a third administration 9 months later at a dose of 380 mg, or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0352] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration 12 months later at a dose of 380 mg of the anti-TRBV9 antibody, a third administration 12 months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 12 months, based on a subject's body weight of 30 to 50 kg.

[0353] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration at least 3 months later at a dose of 495 mg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg at least every 12 months.

[0354] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of an anti-TRBV9 antibody at a dose of 495 mg three months later, a third administration of an anti-TRBV9 antibody at a dose of 495 mg six months later; or nine months later; or 12 months later, and subsequent administration of an anti-TRBV9 antibody at a dose of 495 mg every 12 months.

[0355] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 6 months later at a dose of 495 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 495 mg every 12 months.

[0356] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 9 months later at a dose of 495 mg of the anti-TRBV9 antibody, a third administration 9 months later at a dose of 495 mg of the anti-TRBV9 antibody; or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 495 mg every 12 months.

[0357] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 495 mg, a third administration 12 months later of the anti-TRBV9 antibody at a dose of 495 mg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg every 12 months.

[0358] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration at least 3 months later at a dose of 500 mg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg at least every 12 months.

[0359] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of an anti-TRBV9 antibody at a dose of 500 mg three months later, a third administration of an anti-TRBV9 antibody at a dose of 500 mg six months later; or nine months later; or 12 months later, and subsequent administration of an anti-TRBV9 antibody at a dose of 500 mg every 12 months.

[0360] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 6 months later at a dose of 500 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 500 mg every 12 months.

[0361] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 9 months later at a dose of 500 mg of the anti-TRBV9 antibody, a third administration 9 months later at a dose of 500 mg of the anti-TRBV9 antibody; or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 500 mg every 12 months.

[0362] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 12 months later of an anti-TRBV9 antibody at a dose of 500 mg, a third administration 12 months later of an anti-TRBV9 antibody at a dose of 500 mg, and subsequent administrations of an anti-TRBV9 antibody at a dose of 500 mg every 12 months.

[0363] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration at least 3 months later at a dose of 505 mg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg at least every 12 months.

[0364] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of an anti-TRBV9 antibody at a dose of 505 mg three months later, a third administration of an anti-TRBV9 antibody at a dose of 505 mg six months later; or nine months later; or 12 months later, and subsequent administration of an anti-TRBV9 antibody at a dose of 505 mg every 12 months.

[0365] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 6 months later at a dose of 505 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 505 mg every 12 months.

[0366] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 9 months later at a dose of 505 mg of the anti-TRBV9 antibody, a third administration 9 months later at a dose of 505 mg of the anti-TRBV9 antibody; or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 505 mg every 12 months.

[0367] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 505 mg, a third administration 12 months later of the anti-TRBV9 antibody at a dose of 505 mg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg every 12 months.

[0368] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration at least 3 months later at a dose of 495 mg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg at least every 12 months, based on a subject's body weight of 51 to 89 kg.

[0369] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 51 to 89 kg, a second administration three months later at a dose of 495 mg, a third administration six months later; or nine months later; or 12 months later at a dose of 495 mg, and subsequent administrations of an anti-TRBV9 antibody every 12 months at a dose of 495 mg.

[0370] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 51 to 89 kg, a second administration 6 months later at a dose of 495 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg every 12 months.

[0371] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 51 to 89 kg, a second administration 9 months later at a dose of 495 mg, a third administration 9 months later at a dose of 495 mg, or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 495 mg every 12 months.

[0372] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 12 months later at a dose of 495 mg of the anti-TRBV9 antibody, a third administration 12 months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg every 12 months, based on a subject's body weight of 51 to 89 kg.

[0373] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 51 to 89 kg, a second administration at least 3 months later at a dose of 500 mg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 500 mg at least every 12 months.

[0374] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 51 to 89 kg, a second administration three months later at a dose of 500 mg of the anti-TRBV9 antibody, a third administration six months later; or nine months later; or 12 months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a dose of 500 mg of the anti-TRBV9 antibody.

[0375] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 51 to 89 kg, a second administration 6 months later at a dose of 500 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 500 mg every 12 months.

[0376] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 51 to 89 kg, a second administration 9 months later at a dose of 500 mg, a third administration 9 months later at a dose of 500 mg, or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 500 mg every 12 months.

[0377] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 12 months later at a dose of 500 mg of the anti-TRBV9 antibody, a third administration 12 months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 500 mg every 12 months, based on a subject's body weight of 51 to 89 kg.

[0378] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 51 to 89 kg, a second administration at least 3 months later at a dose of 505 mg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg at least every 12 months.

[0379] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 51 to 89 kg, a second administration three months later at a dose of 505 mg, a third administration six months later; or nine months later; or 12 months later at a dose of 505 mg, and subsequent administrations of an anti-TRBV9 antibody every 12 months at a dose of 505 mg.

[0380] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 51 to 89 kg, a second administration 6 months later at a dose of 505 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 505 mg every 12 months.

[0381] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 51 to 89 kg, a second administration 9 months later at a dose of 505 mg, a third administration 9 months later at a dose of 505 mg, or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 505 mg every 12 months.

[0382] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 12 months later at a dose of 505 mg of the anti-TRBV9 antibody, a third administration 12 months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg every 12 months, based on a subject's body weight of 51 to 89 kg.

[0383] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration at least 3 months later at a dose of 620 mg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg at least every 12 months.

[0384] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg three months later, a third administration of the anti-TRBV9 antibody at a dose of 620 mg six months later; or nine months later; or 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0385] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 6 months later at a dose of 620 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0386] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 9 months later at a dose of 620 mg of the anti-TRBV9 antibody, a third administration 9 months later at a dose of 620 mg of the anti-TRBV9 antibody; or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0387] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 620 mg, a third administration 12 months later of the anti-TRBV9 antibody at a dose of 620 mg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0388] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration at least 3 months later of an anti-TRBV9 antibody at a dose of 625 mg, a third administration at least 6 months later of an anti-TRBV9 antibody at a dose of 625 mg, and subsequent administrations of an anti-TRBV9 antibody at a dose of 625 mg at least every 12 months.

[0389] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg three months later, a third administration of the anti-TRBV9 antibody at a dose of 625 mg six months later; or nine months later; or 12 months later, and subsequent administration of the anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0390] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 6 months later at a dose of 625 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0391] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 9 months later at a dose of 625 mg of the anti-TRBV9 antibody, a third administration 9 months later at a dose of 625 mg of the anti-TRBV9 antibody; or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0392] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 625 mg, a third administration 12 months later of the anti-TRBV9 antibody at a dose of 625 mg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0393] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration at least 3 months later at a dose of 630 mg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg at least every 12 months.

[0394] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of an anti-TRBV9 antibody at a dose of 630 mg three months later, a third administration of an anti-TRBV9 antibody at a dose of 630 mg six months later; or nine months later; or 12 months later, and subsequent administration of an anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0395] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 6 months later at a dose of 630 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0396] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 9 months later at a dose of 630 mg of the anti-TRBV9 antibody, a third administration 9 months later at a dose of 630 mg of the anti-TRBV9 antibody; or a third administration 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0397] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 12 months later of the anti-TRBV9 antibody at a dose of 630 mg, a third administration 12 months later of the anti-TRBV9 antibody at a dose of 630 mg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0398] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 90 to 150 kg, a second administration at least 3 months later at a dose of 620 mg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg at least every 12 months.

[0399] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 90 to 150 kg, a second administration three months later at a dose of 620 mg of the anti-TRBV9 antibody, a third administration six months later; or nine months later; or 12 months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0400] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 90 to 150 kg, a second administration 6 months later at a dose of 620 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0401] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 90 to 150 kg, a second administration 9 months later at a dose of 620 mg, a third administration 9 months later at a dose of 620 mg, or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0402] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 90 to 150 kg, a second administration 12 months later at a dose of 620 mg of the anti-TRBV9 antibody, a third administration 12 months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0403] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 90 to 150 kg, a second administration at least 3 months later at a dose of 625 mg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg at least every 12 months.

[0404] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 90 to 150 kg, a second administration three months later at a dose of 625 mg of the anti-TRBV9 antibody, a third administration six months later; or nine months later; or 12 months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0405] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 90 to 150 kg, a second administration 6 months later at a dose of 625 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0406] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 90 to 150 kg, a second administration 9 months later at a dose of 625 mg, a third administration 9 months later at a dose of 625 mg, or a third administration 12 months later at a dose of 625 mg, and subsequent administrations of an anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0407] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 12 months later at a dose of 625 mg of the anti-TRBV9 antibody, a third administration 12 months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 12 months, based on a subject's body weight of 90 to 150 kg.

[0408] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 90 to 150 kg, a second administration at least 3 months later at a dose of 630 mg, a third administration at least 6 months later at a dose of 630 mg, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg at least every 12 months.

[0409] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 90 to 150 kg, a second administration three months later at a dose of 630 mg of the anti-TRBV9 antibody, a third administration six months later; or nine months later; or 12 months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0410] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 90 to 150 kg, a second administration 6 months later at a dose of 630 mg of the anti-TRBV9 antibody, a third administration 6 months later; or 9 months later; or 12 months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0411] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 90 to 150 kg, a second administration 9 months later at a dose of 630 mg, a third administration 9 months later at a dose of 630 mg, or a third administration 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0412] In some embodiments of the invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 90 to 150 kg, a second administration 12 months later at a dose of 630 mg of the anti-TRBV9 antibody, a third administration 12 months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0413] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need of treatment for the disease or disorder at a dose of 0.03 to 10 mg / kg.

[0414] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need of treatment for the disease or disorder at a dose of 0.03 to 7 mg / kg.

[0415] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need of treatment for the disease or disorder at a dose of 0.3 to 10 mg / kg.

[0416] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need of treatment for the disease or disorder at a dose of 0.3 to 7 mg / kg.

[0417] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need of treatment for the disease or disorder at a dose of 1 to 7 mg / kg.

[0418] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 2 to 7 mg / kg. In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 3 to 7 mg / kg.

[0419] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 4 to 7 mg / kg. In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 5 to 7 mg / kg.

[0420] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 6 to 7 mg / kg. In some embodiments of the invention, the anti-TRBV9 antibody is administered at a dose of 1 mg / kg, or 2 mg / kg, or 3 mg / kg, or 4 mg / kg, or 5 mg / kg, or 6 mg / kg, or 7 mg / kg.

[0421] In some embodiments of the invention, the anti-TRBV9 antibody is administered at a dose of 7.5 mg / kg, or 8 mg / kg, or 8.5 mg / kg, or 9 mg / kg, or 9.5 mg / kg, or 10 mg / kg.

[0422] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least every 3 to 12 months. In some embodiments of the present invention, the anti-TRBV9 antibody is administered every 3 to 12 months.

[0423] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least every 6 to 12 months. In some embodiments of the present invention, the anti-TRBV9 antibody is administered every 6 to 12 months.

[0424] In some embodiments of the invention, the anti-TRBV9 antibody is administered at least every 3 months; or at least every 6 months; or at least every 9 months; or at least every 12 months. In some embodiments of the invention, the anti-TRBV9 antibody is administered every 3 months; or every 6 months; or every 9 months; or every 12 months.

[0425] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need of treatment for the disease or disorder at a dose of 75 to 675 mg.

[0426] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need of treatment for the disease or disorder at a dose of 100 to 650 mg.

[0427] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need of treatment for the disease or disorder at a dose of 75 to 175 mg; or 200 to 300 mg; or 325 to 425 mg; or 450 to 650 mg; or 575 to 675 mg.

[0428] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need of treatment for the disease or disorder at a dose of 100 to 150 mg; or 225 to 275 mg; or 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg.

[0429] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need of treatment for the disease or disorder at a dose of 115 to 135 mg; or 240 to 260 mg; or 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg.

[0430] In some embodiments of the invention, the anti-TRBV9 antibody is administered at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg; or 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg.

[0431] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least every 3 to 12 months. In some embodiments of the present invention, the anti-TRBV9 antibody is administered every 3 to 12 months.

[0432] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least every 6 to 12 months. In some embodiments of the present invention, the anti-TRBV9 antibody is administered every 6 to 12 months.

[0433] In some embodiments of the invention, the anti-TRBV9 antibody is administered at least every 3 months; or at least every 6 months; or at least every 9 months; or at least every 12 months. In some embodiments of the invention, the anti-TRBV9 antibody is administered every 3 months; or every 6 months; or every 9 months; or every 12 months.

[0434] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein a first administration of the anti-TRBV9 antibody to a subject in need of treatment for the disease or disorder is carried out at a dose of 0.015 to 5 mg / kg, which is equal to half the main dose, a second administration of the anti-TRBV9 antibody is carried out at least three months later at a main dose of 0.03 to 10 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are carried out at least every six months at a main dose of 0.03 to 10 mg / kg.

[0435] In some embodiments of the present invention, the use includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.015 to 5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration three months later at a main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months.

[0436] In some embodiments of the present invention, the use includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.015 to 5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration six months later at a main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months.

[0437] In some embodiments of the invention, the use includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.015 to 5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration 9 months later at a main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody every 9 months; or every 12 months.

[0438] In some embodiments of the invention, the use includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.015 to 5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration 12 months later at a main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 0.03 to 10 mg / kg of the anti-TRBV9 antibody.

[0439] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein a first administration of the anti-TRBV9 antibody to a subject in need of treatment for the disease or disorder is carried out at a dose of 0.015 to 3.5 mg / kg, which is equal to half the main dose, a second administration of the anti-TRBV9 antibody is carried out at least three months later at a main dose of 0.03 to 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are carried out at least every six months at a main dose of 0.03 to 7 mg / kg.

[0440] In some embodiments of the present invention, the use includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.015 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration three months later at a main dose of 0.03 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 0.03 to 7 mg / kg of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months.

[0441] In some embodiments of the present invention, the use includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.015 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration six months later at a main dose of 0.03 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 0.03 to 7 mg / kg of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months.

[0442] In some embodiments of the invention, the use includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.015 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration 9 months later at a main dose of 0.03 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 0.03 to 7 mg / kg of the anti-TRBV9 antibody every 9 months; or every 12 months.

[0443] In some embodiments of the invention, the use includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.015 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration 12 months later at a main dose of 0.03 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 0.03 to 7 mg / kg of the anti-TRBV9 antibody.

[0444] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein a first administration of the anti-TRBV9 antibody to a subject in need of treatment for the disease or disorder is carried out at a dose of 0.15 to 5 mg / kg, which is equal to half the main dose, a second administration of the anti-TRBV9 antibody is carried out at least three months later at a main dose of 0.3 to 10 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are carried out at least every six months at a main dose of 0.3 to 10 mg / kg.

[0445] In some embodiments of the present invention, the use includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.15 to 5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration three months later at a main dose of 0.3 to 10 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 0.3 to 10 mg / kg of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months.

[0446] In some embodiments of the present invention, the use includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.15 to 5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration six months later at a main dose of 0.3 to 10 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 0.3 to 10 mg / kg of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months.

[0447] In some embodiments of the present invention, the use includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.15 to 5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration 9 months later at a main dose of 0.3 to 10 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 0.3 to 10 mg / kg of the anti-TRBV9 antibody every 9 months; or every 12 months.

[0448] In some embodiments of the invention, the use includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.15 to 5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration 12 months later at a main dose of 0.3 to 10 mg / kg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 0.3 to 10 mg / kg of the anti-TRBV9 antibody.

[0449] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein a first administration of the anti-TRBV9 antibody to a subject in need of treatment for the disease or disorder is carried out at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose, a second administration of the anti-TRBV9 antibody is carried out at least three months later at a main dose of 0.3 to 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are carried out at least every six months at a main dose of 0.3 to 7 mg / kg.

[0450] In some embodiments of the present invention, the use includes a first administration to a subject in need of treatment for a disease or disorder, at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration of the anti-TRBV9 antibody three months later at a main dose of 0.3 to 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 0.3 to 7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0451] In some embodiments of the present invention, the use includes a first administration to a subject in need of treatment for a disease or disorder, at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration of the anti-TRBV9 antibody is administered 6 months later at a main dose of 0.3 to 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered every 6 months; or every 9 months; or every 12 months at a main dose of 0.3 to 7 mg / kg.

[0452] In some embodiments of the present invention, the use includes a first administration to a subject in need of treatment for a disease or disorder, at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration of the anti-TRBV9 antibody 9 months later at a main dose of 0.3 to 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 0.3 to 7 mg / kg every 9 months; or every 12 months.

[0453] In some embodiments of the present invention, the use includes a first administration to a subject in need of treatment for a disease or disorder, at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration of the anti-TRBV9 antibody 12 months later at a main dose of 0.3 to 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody every 12 months at a main dose of 0.3 to 7 mg / kg.

[0454] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein a first administration of the anti-TRBV9 antibody to a subject in need of treatment for the disease or disorder is carried out at a dose of 0.5 to 3.5 mg / kg, which is equal to half the main dose, a second administration of the anti-TRBV9 antibody is carried out at least three months later at a main dose of 1 to 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are carried out at least every six months at a main dose of 1 to 7 mg / kg.

[0455] In some aspects, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein a first administration of the anti-TRBV9 antibody to a subject in need of treatment for the disease or disorder is carried out at a dose of 0.5 to 3.5 mg / kg, which is equal to half the main dose, a second administration of the anti-TRBV9 antibody is carried out three months later at a main dose of 1 to 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are carried out every 6 months; or every 9 months; or every 12 months at a main dose of 1 to 7 mg / kg.

[0456] In some embodiments of the present invention, the use includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration six months later at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administration of the main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody every six months; or every nine months; or every 12 months.

[0457] In some embodiments of the invention, the use includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration 9 months later at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody every 9 months; or every 12 months.

[0458] In some embodiments of the invention, the use includes a first administration to a subject in need of treatment for a disease or disorder at a dose of 0.15 to 3.5 mg / kg, which is equal to half the main dose of the anti-TRBV9 antibody, a second administration 12 months later at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 1 to 7 mg / kg of the anti-TRBV9 antibody.

[0459] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody is administered at least 3 months later at a dose of 1 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 6 months at a dose of 1 mg / kg.

[0460] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is administered at a dose of 0.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered three months later at a dose of 1 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 1 mg / kg every 6 months; or every 9 months; or every 12 months.

[0461] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is administered at a dose of 0.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered 6 months later at a dose of 1 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 1 mg / kg every 6 months; or every 9 months; or every 12 months.

[0462] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody is administered 9 months later at a dose of 1 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 1 mg / kg every 9 months; or every 12 months.

[0463] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody is administered 12 months later at a dose of 1 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered every 12 months at a dose of 1 mg / kg.

[0464] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody is administered at least 3 months later at a dose of 2 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 6 months at a dose of 2 mg / kg.

[0465] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody is administered three months later at a dose of 2 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 2 mg / kg every 6 months; or every 9 months; or every 12 months.

[0466] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody is administered 6 months later at a dose of 2 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 2 mg / kg every 6 months; or every 9 months; or every 12 months.

[0467] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody is administered 9 months later at a dose of 2 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 2 mg / kg every 9 months; or every 12 months.

[0468] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody is administered 12 months later at a dose of 2 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered every 12 months at a dose of 2 mg / kg.

[0469] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 1.5 mg / kg, a second administration of the anti-TRBV9 antibody is administered at least 3 months later at a dose of 3 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 6 months at a dose of 3 mg / kg.

[0470] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is administered at a dose of 1.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered three months later at a dose of 3 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 3 mg / kg every 6 months; or every 9 months; or every 12 months.

[0471] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is administered at a dose of 1.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered 6 months later at a dose of 3 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 3 mg / kg every 6 months; or every 9 months; or every 12 months.

[0472] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is administered at a dose of 1.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered 9 months later at a dose of 3 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 3 mg / kg every 9 months; or every 12 months.

[0473] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 1.5 mg / kg, a second administration of the anti-TRBV9 antibody is administered 12 months later at a dose of 3 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered every 12 months at a dose of 3 mg / kg.

[0474] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody is administered at least 3 months later at a dose of 4 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 6 months at a dose of 4 mg / kg.

[0475] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody is administered three months later at a dose of 4 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 4 mg / kg every 6 months; or every 9 months; or every 12 months.

[0476] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody is administered 6 months later at a dose of 4 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 4 mg / kg every 6 months; or every 9 months; or every 12 months.

[0477] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody is administered 9 months later at a dose of 4 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 4 mg / kg every 9 months; or every 12 months.

[0478] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody is administered 12 months later at a dose of 4 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered every 12 months at a dose of 4 mg / kg.

[0479] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 2.5 mg / kg, a second administration of the anti-TRBV9 antibody is administered at least 3 months later at a dose of 5 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 6 months at a dose of 5 mg / kg.

[0480] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is administered at a dose of 2.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered three months later at a dose of 5 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 5 mg / kg every 6 months; or every 9 months; or every 12 months.

[0481] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is administered at a dose of 2.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered 6 months later at a dose of 5 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 5 mg / kg every 6 months; or every 9 months; or every 12 months.

[0482] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is administered at a dose of 2.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered 9 months later at a dose of 5 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 5 mg / kg every 9 months; or every 12 months.

[0483] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 2.5 mg / kg, a second administration of the anti-TRBV9 antibody is administered 12 months later at a dose of 5 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered every 12 months at a dose of 5 mg / kg.

[0484] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody is administered at least 3 months later at a dose of 6 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 6 months at a dose of 6 mg / kg.

[0485] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody is administered three months later at a dose of 6 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 6 mg / kg every 6 months; or every 9 months; or every 12 months.

[0486] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody is administered 6 months later at a dose of 6 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 6 mg / kg every 6 months; or every 9 months; or every 12 months.

[0487] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody is administered 9 months later at a dose of 6 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 6 mg / kg every 9 months; or every 12 months.

[0488] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody is administered 12 months later at a dose of 6 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered every 12 months at a dose of 6 mg / kg.

[0489] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 3.5 mg / kg, a second administration of the anti-TRBV9 antibody is administered at least 3 months later at a dose of 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 6 months at a dose of 7 mg / kg.

[0490] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is administered at a dose of 3.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered three months later at a dose of 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0491] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is administered at a dose of 3.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered 6 months later at a dose of 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0492] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is administered at a dose of 3.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered 9 months later at a dose of 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 7 mg / kg every 9 months; or every 12 months.

[0493] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 3.5 mg / kg, a second administration of the anti-TRBV9 antibody is administered 12 months later at a dose of 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered every 12 months at a dose of 7 mg / kg.

[0494] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 4 mg / kg, a second administration of the anti-TRBV9 antibody is administered three months later at a dose of 8 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 8 mg / kg every 6 months; or every 9 months; or every 12 months.

[0495] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is administered at a dose of 4 mg / kg, the second administration of the anti-TRBV9 antibody is administered 6 months later at a dose of 8 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 8 mg / kg every 6 months; or every 9 months; or every 12 months.

[0496] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is administered at a dose of 4 mg / kg, the second administration of the anti-TRBV9 antibody is administered 9 months later at a dose of 8 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 8 mg / kg every 9 months; or every 12 months.

[0497] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 4 mg / kg, a second administration of the anti-TRBV9 antibody is administered 12 months later at a dose of 8 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered every 12 months at a dose of 8 mg / kg.

[0498] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is administered at a dose of 4.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered three months later at a dose of 9 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 9 mg / kg every 6 months; or every 9 months; or every 12 months.

[0499] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is administered at a dose of 4.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered 6 months later at a dose of 9 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 9 mg / kg every 6 months; or every 9 months; or every 12 months.

[0500] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is administered at a dose of 4.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered 9 months later at a dose of 9 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 9 mg / kg every 9 months; or every 12 months.

[0501] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 4.5 mg / kg, a second administration of the anti-TRBV9 antibody is administered 12 months later at a dose of 9 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered every 12 months at a dose of 9 mg / kg.

[0502] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 5 mg / kg, a second administration of the anti-TRBV9 antibody is administered three months later at a dose of 10 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0503] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 5 mg / kg, a second administration of the anti-TRBV9 antibody is administered 6 months later at a dose of 10 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0504] In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 5 mg / kg, a second administration of the anti-TRBV9 antibody is administered 9 months later at a dose of 10 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at a dose of 10 mg / kg every 9 months; or every 12 months.

[0505] (viii) In some embodiments of the present invention, a first administration of an anti-TRBV9 antibody is administered at a dose of 5 mg / kg, a second administration of the anti-TRBV9 antibody is administered 12 months later at a dose of 10 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered every 12 months at a dose of 10 mg / kg.

[0506] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein a first administration of the anti-TRBV9 antibody to a subject in need of treatment for the disease or disorder is carried out at a dose of 75 to 300 mg, a second administration of the anti-TRBV9 antibody is carried out at least three months later at a main dose of 325 to 675 mg, and subsequent administrations of the anti-TRBV9 antibody are carried out at least every six months at a main dose of 325 to 675 mg.

[0507] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 75 to 300 mg to a subject in need of treatment for a disease or disorder, a second administration three months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, and subsequent administration of the main dose of 325 to 675 mg of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months.

[0508] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 75 to 300 mg to a subject in need of treatment for a disease or disorder, a second administration six months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, and subsequent administration of the main dose of 325 to 675 mg of the anti-TRBV9 antibody every six months; or every nine months; or every 12 months.

[0509] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 75 to 300 mg to a subject in need of treatment for a disease or disorder, a second administration 9 months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, and subsequent administration of the main dose of 325 to 675 mg of the anti-TRBV9 antibody every 9 months; or every 12 months.

[0510] Some embodiments of the invention include a first administration to a subject in need of treatment for a disease or disorder of an anti-TRBV9 antibody at a dose of 75 to 300 mg, a second administration 12 months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months of a main dose of 325 to 675 mg of the anti-TRBV9 antibody.

[0511] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein a first administration of the anti-TRBV9 antibody to a subject in need of treatment for the disease or disorder is carried out at a dose of 100 to 275 mg, a second administration of the anti-TRBV9 antibody is carried out at least three months later at a main dose of 350 to 650 mg, and subsequent administrations of the anti-TRBV9 antibody are carried out at least every six months at a main dose of 350 to 650 mg.

[0512] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 100 to 275 mg to a subject in need of treatment for a disease or disorder, a second administration three months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, and subsequent administration of the main dose of 350 to 650 mg of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months.

[0513] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 100 to 275 mg to a subject in need of treatment for a disease or disorder, a second administration six months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, and subsequent administration of the main dose of 350 to 650 mg of the anti-TRBV9 antibody every six months; or every nine months; or every 12 months.

[0514] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 100 to 275 mg to a subject in need of treatment for a disease or disorder, a second administration 9 months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 to 650 mg every 9 months; or every 12 months.

[0515] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 100 to 275 mg to a subject in need of treatment for a disease or disorder, a second administration 12 months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 to 650 mg every 12 months.

[0516] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein a first administration of the anti-TRBV9 antibody to a subject in need of treatment for the disease or disorder is carried out at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration of the anti-TRBV9 antibody is carried out at least three months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg, and subsequent administrations of the anti-TRBV9 antibody are carried out at least every six months at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg.

[0517] In some embodiments of the invention, the use comprises: (i) administering to a subject in need of treatment for a disease or disorder a first administration of an anti-TRBV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration three months later of a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg of the anti-TRBV9 antibody, and subsequent administrations every six months of a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg of the anti-TRBV9 antibody; or (ii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration three months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every nine months at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (iii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration 3 months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (iv) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration six months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every six months at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (v) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration six months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every nine months at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (vi) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration 6 months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (vii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration 9 months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every 9 months at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (viii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration 9 months later at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of an anti-TRBV9 antibody; or (iх) A subject in need of treatment for a disease or disorder, comprising a first administration of an anti-TRBV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration 12 months later at a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg of an anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg of an anti-TRBV9 antibody. Includes.

[0518] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein a first administration of the anti-TRBV9 antibody to a subject in need of treatment for the disease or disorder is carried out at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration of the anti-TRBV9 antibody is carried out at least three months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg, and subsequent administrations of the anti-TRBV9 antibody are carried out at least every six months with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg.

[0519] In some embodiments of the invention, the use comprises: (i) administering to a subject in need of treatment for a disease or disorder a first administration of an anti-TRBV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration three months later with a main dose of 365-385 mg; or 490-510 mg; or 615-635 mg of the anti-TRBV9 antibody, and subsequent administrations every six months with a main dose of 365-385 mg; or 490-510 mg; or 615-635 mg of the anti-TRBV9 antibody; or (ii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration three months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every nine months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (iii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 3 months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (iv) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration six months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every six months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (v) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration six months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of an anti-TRBV9 antibody, and subsequent administrations every nine months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of an anti-TRBV9 antibody; or (vi) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 6 months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (vii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 9 months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 9 months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (viii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 9 months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody; or (ix) A subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration 12 months later at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody. Includes.

[0520] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein a first administration of the anti-TRBV9 antibody is administered at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of the anti-TRBV9 antibody is administered at least 3 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 6 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg.

[0521] In some aspects, the present invention provides a use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising: (i) administering to a subject in need of treatment for the disease or disorder a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration three months later of a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every six months of a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; or (ii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration 3 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every 9 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; or (iii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration 3 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; or (iv) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration six months later of a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every six months of a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; or (v) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration 6 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every 9 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; or (vi) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration 6 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; or (vii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration 9 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every 9 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; or (viii) a subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration 9 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody; or (ix) A subject in need of treatment for a disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration 12 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations every 12 months at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody. is, regarding use.

[0522] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration at least three months later of an anti-TRBV9 antibody at a dose of 370 mg, and subsequent administrations of an anti-TRBV9 antibody at a dose of 370 mg at least every six months.

[0523] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration at least three months later of an anti-TRBV9 antibody at a dose of 370 mg, and subsequent administrations of an anti-TRBV9 antibody at a dose of 370 mg at least every six months.

[0524] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration three months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 370 mg every six months; or every nine months; or every 12 months.

[0525] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration six months later of an anti-TRBV9 antibody at a dose of 370 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 370 mg every six months; or every nine months; or every 12 months.

[0526] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration 9 months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 370 mg every 9 months; or every 12 months.

[0527] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration 12 months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 12 months.

[0528] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration at least three months later of an anti-TRBV9 antibody at a dose of 375 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 375 mg at least every six months.

[0529] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration three months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 375 mg every six months; or every nine months; or every 12 months.

[0530] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration six months later of an anti-TRBV9 antibody at a dose of 375 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 375 mg every six months; or every nine months; or every 12 months.

[0531] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration 9 months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 375 mg every 9 months; or every 12 months.

[0532] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration 12 months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 12 months.

[0533] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration at least three months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg at least every six months.

[0534] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration three months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 380 mg every six months; or every nine months; or every 12 months.

[0535] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration six months later of an anti-TRBV9 antibody at a dose of 380 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 380 mg every six months; or every nine months; or every 12 months.

[0536] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration 9 months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 380 mg every 9 months; or every 12 months.

[0537] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration 12 months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0538] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, based on a subject's body weight of 30 to 50 kg, a second administration at least three months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg at least every six months.

[0539] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, based on a subject's body weight of 30 to 50 kg, a second administration three months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 370 mg every six months; or every nine months; or every 12 months.

[0540] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, based on a subject's body weight of 30 to 50 kg, a second administration six months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 370 mg every six months; or every nine months; or every 12 months.

[0541] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, based on a subject's body weight of 30 to 50 kg, a second administration 9 months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 370 mg every 9 months; or every 12 months.

[0542] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration 12 months later at a dose of 370 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 12 months, based on a subject's body weight of 30 to 50 kg.

[0543] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, based on a subject's body weight of 30 to 50 kg, a second administration at least three months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg at least every six months.

[0544] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, based on a subject's body weight of 30 to 50 kg, a second administration three months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 375 mg every six months; or every nine months; or every 12 months.

[0545] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, based on a subject's body weight of 30 to 50 kg, a second administration six months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 375 mg every six months; or every nine months; or every 12 months.

[0546] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, based on a subject's body weight of 30 to 50 kg, a second administration 9 months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 375 mg every 9 months; or every 12 months.

[0547] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration 12 months later at a dose of 375 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 375 mg every 12 months, based on a subject's body weight of 30 to 50 kg.

[0548] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, based on a subject's body weight of 30 to 50 kg, a second administration at least three months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg at least every six months.

[0549] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, based on a subject's body weight of 30 to 50 kg, a second administration three months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 380 mg every six months; or every nine months; or every 12 months.

[0550] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, based on a subject's body weight of 30 to 50 kg, a second administration six months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 380 mg every six months; or every nine months; or every 12 months.

[0551] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, based on a subject's body weight of 30 to 50 kg, a second administration 9 months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 380 mg every 9 months; or every 12 months.

[0552] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration 12 months later at a dose of 380 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 12 months, based on a subject's body weight of 30 to 50 kg.

[0553] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration at least three months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg at least every six months.

[0554] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration three months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 495 mg every six months; or every nine months; or every 12 months.

[0555] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration six months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 495 mg every six months; or every nine months; or every 12 months.

[0556] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 9 months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 495 mg every 9 months; or every 12 months.

[0557] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 12 months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg every 12 months.

[0558] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration at least three months later of an anti-TRBV9 antibody at a dose of 500 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 500 mg at least every six months.

[0559] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration three months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 500 mg every six months; or every nine months; or every 12 months.

[0560] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration six months later of an anti-TRBV9 antibody at a dose of 500 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 500 mg every six months; or every nine months; or every 12 months.

[0561] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 9 months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 500 mg every 9 months; or every 12 months.

[0562] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 12 months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 500 mg every 12 months.

[0563] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration at least three months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg at least every six months.

[0564] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration three months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 505 mg every six months; or every nine months; or every 12 months.

[0565] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration six months later of an anti-TRBV9 antibody at a dose of 505 mg, and subsequent administration of an anti-TRBV9 antibody at a dose of 505 mg every six months; or every nine months; or every 12 months.

[0566] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 9 months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 505 mg every 9 months; or every 12 months.

[0567] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 12 months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg every 12 months.

[0568] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 51 to 89 kg, a second administration at least three months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg at least every six months.

[0569] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration three months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 495 mg every six months; or every nine months; or every 12 months, based on a subject's body weight of 51 to 89 kg.

[0570] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration six months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 495 mg every six months; or every nine months; or every 12 months, based on a subject's body weight of 51 to 89 kg.

[0571] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 51 to 89 kg, a second administration 9 months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 495 mg every 9 months; or every 12 months.

[0572] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 12 months later at a dose of 495 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 495 mg every 12 months, based on a subject's body weight of 51 to 89 kg.

[0573] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 51 to 89 kg, a second administration at least three months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 500 mg at least every six months.

[0574] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration three months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 500 mg every six months; or every nine months; or every 12 months, based on a subject's body weight of 51 to 89 kg.

[0575] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration six months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 500 mg every six months; or every nine months; or every 12 months, based on a subject's body weight of 51 to 89 kg.

[0576] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, based on a subject's body weight of 51 to 89 kg, a second administration 9 months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 500 mg every 9 months; or every 12 months.

[0577] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 12 months later at a dose of 500 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 500 mg every 12 months, based on a subject's body weight of 51 to 89 kg.

[0578] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 51 to 89 kg, a second administration at least three months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg at least every six months.

[0579] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 51 to 89 kg, a second administration three months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 505 mg every six months; or every nine months; or every 12 months.

[0580] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 51 to 89 kg, a second administration six months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 505 mg every six months; or every nine months; or every 12 months.

[0581] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, based on a subject's body weight of 51 to 89 kg, a second administration 9 months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 505 mg every 9 months; or every 12 months.

[0582] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 12 months later at a dose of 505 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 505 mg every 12 months, based on a subject's body weight of 51 to 89 kg.

[0583] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration at least three months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg at least every six months.

[0584] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration three months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 620 mg every six months; or every nine months; or every 12 months.

[0585] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration six months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 620 mg every six months; or every nine months; or every 12 months.

[0586] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 9 months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 620 mg every 9 months; or every 12 months.

[0587] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration 12 months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0588] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration at least three months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg at least every six months.

[0589] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration three months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 625 mg every six months; or every nine months; or every 12 months.

[0590] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration six months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 625 mg every six months; or every nine months; or every 12 months.

[0591] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 9 months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 625 mg every 9 months; or every 12 months.

[0592] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration 12 months later at a dose of 625 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0593] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration at least three months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg at least every six months.

[0594] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration three months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 630 mg every six months; or every nine months; or every 12 months.

[0595] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration six months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administration of the anti-TRBV9 antibody at a dose of 630 mg every six months; or every nine months; or every 12 months.

[0596] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 9 months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 630 mg every 9 months; or every 12 months.

[0597] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration 12 months later at a dose of 630 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0598] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 90 to 150 kg, a second administration at least three months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg at least every six months.

[0599] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 90 to 150 kg, a second administration three months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 620 mg every six months; or every nine months; or every 12 months.

[0600] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 90 to 150 kg, a second administration six months later at a dose of 620 mg of the anti-TRBV9 antibody, and subsequent administration of an anti-TRBV9 antibody at a dose of 620 mg every six months; or every nine months; or every 12 months.

[0601] In some embodiments of the invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, based on a subject's body weight of 90 to 150 kg, a second administration 9 months later at a dose of 620 mg of the anti-TRBV9 antibody, and su...

Claims

1. A method for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising administering to a subject in need of treatment for said disease or disorder an anti-TRBV9 antibody at a dose of 0.03 to 10 mg / kg or 75 to 675 mg.

2. 10. The method of claim 1 for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising administering to a subject in need of treatment for the disease or disorder an anti-TRBV9 antibody at a dose of 0.03 to 7 mg / kg.

3. 10. The method of claim 1 for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising administering to a subject in need of treatment for the disease or disorder an anti-TRBV9 antibody at a dose of 100 to 650 mg.

4. 2. The method of claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 1 to 7 mg / kg.

5. 2. The method of claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 3 to 7 mg / kg.

6. 2. The method of claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 5 to 7 mg / kg.

7. 10. The method of claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 75 to 175 mg; or 200 to 300 mg; or 325 to 425 mg; or 450 to 650 mg; or 575 to 675 mg.

8. 10. The method of claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 100 to 150 mg; or 225 to 275 mg; or 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg.

9. 10. The method of claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 115 to 135 mg; or 240 to 260 mg; or 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg.

10. The anti-TRBV9 antibody a dose of 1 mg / kg, or 2 mg / kg, or 3 mg / kg, or 4 mg / kg, or 5 mg / kg, or 6 mg / kg, or 7 mg / kg; or or 245 mg; or 250 mg; or 255 mg; or 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg doses, 2. The method of claim 1, wherein the

11. The method of any one of claims 1 to 10, wherein the anti-TRBV9 antibody is administered at least every 3 to 12 months.

12. The method of any one of claims 1 to 10, wherein the anti-TRBV9 antibody is administered at least every 6 to 12 months.

13. the anti-TRBV9 antibody is administered at least every three months; or the anti-TRBV9 antibody is administered at least every six months; or the anti-TRBV9 antibody is administered at least every 9 months; or The anti-TRBV9 antibody is administered at least every 12 months. The method according to any one of claims 1 to 10.

14. 1. A method of treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising: (i) a first administration to a subject in need of treatment for said disease or disorder at a dose of 0.5 to 5 mg / kg, which is equal to half of the main dose of an anti-TRBV9 antibody, a second administration at least three months later at a main dose of 1 to 10 mg / kg of an anti-TRBV9 antibody, and subsequent administrations at least every six months at a main dose of 1 to 10 mg / kg of an anti-TRBV9 antibody; or (ii) a first administration of an anti-TRBV9 antibody at a dose of 75 to 300 mg, a second administration at least three months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 325 to 675 mg at least every six months to a subject in need of treatment for said disease or disorder; A method comprising:

15. 15. The method of claim 14, wherein the method comprises: (i) a first administration to a subject in need of treatment for said disease or disorder at a dose of 0.5 to 3.5 mg / kg, which is equal to half of the main dose of an anti-TRBV9 antibody, a second administration at least three months later at a main dose of 1 to 7 mg / kg of an anti-TRBV9 antibody, and subsequent administrations at least every six months at a main dose of 1 to 7 mg / kg of an anti-TRBV9 antibody; or (ii) a subject in need of treatment for said disease or disorder, comprising a first administration of an anti-TRBV9 antibody at a dose of 100 to 275 mg, a second administration at least 3 months later with a main dose of 350 to 650 mg of the anti-TRBV9 antibody, a third administration at least 6 months later with a main dose of 350 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 to 650 mg at least every 12 months; method.

16. (i) a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration at least three months later at a dose of 1 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 1 mg / kg at least every six months; or (ii) a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration at least 3 months later at a dose of 2 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 2 mg / kg at least every 6 months; or (iii) a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration at least three months later at a dose of 3 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 3 mg / kg at least every six months; or (iv) a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration at least 3 months later at a dose of 5 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 5 mg / kg at least every 6 months; or (v) a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg, a second administration at least 3 months later at a dose of 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 7 mg / kg at least every 6 months.

15. The method of claim 14, comprising:

17. 15. The method of claim 14, comprising a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration at least three months later with a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations at least every six months thereafter with a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody.

18. 15. The method of claim 14, comprising a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration at least three months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations at least every six months with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody.

19. 15. The method of claim 14, comprising a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration at least three months later with a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations at least every six months with a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody.

20. 1. A method of treating a disease or disorder mediated by T lymphocytes that have a TRBV9 segment in their T cell receptor, comprising: (i) a first administration to a subject in need of treatment for said disease or disorder at a dose of 0.5 to 5 mg / kg, which is equal to half of the main dose of an anti-TRBV9 antibody, a second administration at least 3 months later at a main dose of 1 to 10 mg / kg of an anti-TRBV9 antibody, a third administration at least 6 months later at a main dose of 1 to 10 mg / kg of an anti-TRBV9 antibody, and subsequent administrations at least every 12 months at a main dose of 1 to 10 mg / kg of an anti-TRBV9 antibody; or (ii) a first administration of an anti-TRBV9 antibody at a dose of 75 to 300 mg, a second administration at least 3 months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, a third administration at least 6 months later of a main dose of 325 to 675 mg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 325 to 675 mg of the anti-TRBV9 antibody at least every 12 months to a subject in need of treatment for said disease or disorder; A method comprising:

21. 21. The method of claim 20, wherein the method comprises: (i) a first administration to a subject in need of treatment for said disease or disorder at a dose of 0.5 to 3.5 mg / kg, which is equal to half of the main dose of an anti-TRBV9 antibody, a second administration at least three months later at a main dose of 1 to 7 mg / kg of an anti-TRBV9 antibody, a third administration at least six months later at a main dose of 1 to 7 mg / kg of an anti-TRBV9 antibody, and subsequent administrations at least every 12 months at a main dose of 1 to 7 mg / kg of an anti-TRBV9 antibody; or (ii) a subject in need of treatment for said disease or disorder, a first administration of an anti-TRBV9 antibody at a dose of 100 to 275 mg, a second administration at least 3 months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, a third administration at least 6 months later of a main dose of 350 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations of the main dose of 350 to 650 mg of the anti-TRBV9 antibody at least every 12 months; A method comprising:

22. (i) a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration at least 3 months later at a dose of 1 mg / kg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 1 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 1 mg / kg at least every 12 months; or (ii) a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration at least 3 months later at a dose of 2 mg / kg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 2 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 2 mg / kg at least every 12 months; or (iii) a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration at least 3 months later at a dose of 3 mg / kg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 3 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 3 mg / kg at least every 12 months; or (iv) a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration at least 3 months later at a dose of 5 mg / kg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 51 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 5 mg / kg at least every 12 months; or (v) administering to a subject in need of treatment for said disease or disorder a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg, a second administration at least 3 months later at a dose of 7 mg / kg of the anti-TRBV9 antibody, a third administration at least 6 months later at a dose of 7 mg / kg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a dose of 7 mg / kg at least every 12 months.

21. The method of claim 20, comprising:

23. 21. The method of claim 20, comprising a first administration of an anti-TRBV9 antibody at a dose of 100-150 mg; or 225-275 mg; a second administration at least three months later with a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg of the anti-TRBV9 antibody; a third administration at least six months later with a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg of the anti-TRBV9 antibody; and subsequent administrations of an anti-TRBV9 antibody at a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least every 12 months to a subject in need of treatment for the disease or disorder.

24. 21. The method of claim 20, comprising a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration at least three months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations at least every six months with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody.

25. a first administration at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg of an anti-TRBV9 antibody, a second administration at least 3 months later at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of an anti-TRBV9 antibody, or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the main dose at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least every 12 months.

26. The anti-TRBV9 antibody 1) (a) HCDR1 having the amino acid sequence of SEQ ID NO: 1; (b) an HCDR2 having the amino acid sequence of SEQ ID NO: 2; and (c) an HCDR3 having an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO:

6. a heavy chain variable domain comprising: 2) (a) an LCDR1 having the amino acid sequence of SEQ ID NO: 7; (b) an LCDR2 having the amino acid sequence of SEQ ID NO: 8; and (c) an LCDR3 having the amino acid sequence of SEQ ID NO: 9 a light chain variable domain comprising 21. The method of claim 1, 14, or 20, comprising:

27. The anti-TRBV9 antibody 1) (a) HCDR1 having the amino acid sequence of SEQ ID NO: 1; (b) an HCDR2 having the amino acid sequence of SEQ ID NO: 2; and (c) HCDR3 having the amino acid sequence of SEQ ID NO: 4 a heavy chain variable domain comprising: 2) (a) an LCDR1 having the amino acid sequence of SEQ ID NO: 7; (b) an LCDR2 having the amino acid sequence of SEQ ID NO: 8; and (c) an LCDR3 having the amino acid sequence of SEQ ID NO: 9 a light chain variable domain comprising 27. The method of claim 26, comprising:

28. 27. The method of claim 26, wherein the anti-TRBV9 antibody is a full-length antibody and is of the human IgG1, IgG2, IgG3, or IgG4 isotype.

29. the anti-TRBV9 antibody comprises a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 14 and a light chain variable domain 7 having the amino acid sequence of SEQ ID NO: 17; or 27. The method of claim 26, comprising a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 15 and a light chain variable domain having the amino acid sequence of SEQ ID NO:

17.

30. the anti-TRBV9 antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 22 and a light chain having the amino acid sequence of SEQ ID NO: 25; or a heavy chain having the amino acid sequence of SEQ ID NO:23, and a light chain having the amino acid sequence of SEQ ID NO:25 27. The method of claim 26, comprising:

31. 21. The method of any one of claims 1, 14, and 20, wherein the disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor is selected from the group consisting of arthropathy, inflammatory bowel disease, eye disease, systemic vasculitis, circulatory system disease, kidney disease, digestive system disease, and lymphoproliferative disorder.

32. 21. The method of any one of claims 1, 14, and 20, wherein the disease or disorder mediated by T lymphocytes harboring a TRBV9 segment in their T cell receptor is selected from the group consisting of spondyloarthritis, sacroiliitis associated with psoriasis, sacroiliitis associated with inflammatory bowel disease, undiagnosed oligoarthropathy, juvenile spondylitis / enthesitis-associated arthritis, juvenile ankylosing spondylitis (enthesitis-associated arthritis), juvenile arthritis, undiagnosed juvenile arthritis, ulcerative colitis, Crohn's disease, non-infectious uveitis, anterior uveitis, Behcet's disease, aortitis, fibrosis of the aortic and / or mitral valve leaflets with regurgitation, rhythm disorders, conduction disorders, left ventricular dysfunction, pericarditis, myocarditis, IgA nephropathy, celiac disease, T-cell lymphoma, and T-cell leukemia.

33. 33. The method of claim 32, wherein the spondyloarthritis is axial spondyloarthritis (ankylosing spondylitis) meeting radiographic criteria, axial spondyloarthritis not meeting radiographic criteria, axial spondyloarthritis, peripheral spondyloarthritis, psoriatic arthritis, spondyloarthritis associated with inflammatory bowel disease, reactive arthritis, or undiagnosed peripheral spondyloarthritis.

34. 33. The method of claim 32, wherein the spondyloarthritis is axial spondyloarthritis (ankylosing spondylitis) meeting radiographic criteria in patients who do not respond adequately to standard treatment, axial spondyloarthritis not meeting radiographic criteria in patients who do not respond adequately to standard treatment, axial spondyloarthritis in patients who do not respond adequately to standard treatment, peripheral spondyloarthritis in patients who do not respond adequately to standard treatment, psoriatic arthritis in patients who do not respond adequately to standard treatment, spondyloarthritis associated with inflammatory bowel disease in patients who do not respond adequately to standard treatment, reactive arthritis in patients who do not respond adequately to standard treatment, or undiagnosed peripheral spondyloarthritis in patients who do not respond adequately to standard treatment.

35. A use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need of treatment for the disease or disorder at a dose of 0.03 to 10 mg / kg or at a dose of 75 to 675 mg.

36. 36. The use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor according to claim 35, wherein the anti-TRBV9 antibody is administered to a subject in need of treatment for the disease or disorder at a dose of 0.03 to 7 mg / kg.

37. 36. The use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor according to claim 35, wherein the anti-TRBV9 antibody is administered to a subject in need of treatment for the disease or disorder at a dose of 100 to 650 mg.

38. The use of claim 35, wherein the anti-TRBV9 antibody is administered at a dose of 1 to 7 mg / kg.

39. The use of claim 35, wherein the anti-TRBV9 antibody is administered at a dose of 3 to 7 mg / kg.

40. The use of claim 35, wherein the anti-TRBV9 antibody is administered at a dose of 5 to 7 mg / kg.

41. 36. The use of claim 35, wherein the anti-TRBV9 antibody is administered at any of the following doses: 75 to 175 mg; or 200 to 300 mg; or 325 to 425 mg; or 450 to 650 mg; or 575 to 675 mg.

42. 36. The use of claim 35, wherein the anti-TRBV9 antibody is administered at a dose of 100 to 150 mg; or 225 to 275 mg; or 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg.

43. 36. The use of claim 35, wherein the anti-TRBV9 antibody is administered at a dose of 115 to 135 mg; or 240 to 260 mg; or 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg.

44. the anti-TRBV9 antibody is administered at a dose of 1 mg / kg, or 2 mg / kg, or 3 mg / kg, or 4 mg / kg, or 5 mg / kg, or 6 mg / kg, or 7 mg / kg; or 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg; or 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg.

45. The use of any one of claims 35 to 44, wherein the anti-TRBV9 antibody is administered at least every 3 to 12 months.

46. The use of any one of claims 35 to 44, wherein the anti-TRBV9 antibody is administered at least every 6 to 12 months.

47. the anti-TRBV9 antibody is administered at least every three months; or the anti-TRBV9 antibody is administered at least every six months; or the anti-TRBV9 antibody is administered at least every 9 months; or The anti-TRBV9 antibody is administered at least every 12 months. Use according to any one of claims 35 to 44.

48. 1. Use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, comprising: (i) a first administration of an anti-TRBV9 antibody to a subject in need of treatment for said disease or disorder is carried out at a dose of 0.5 to 5 mg / kg, which is equal to half of the main dose, a second administration of the anti-TRBV9 antibody is carried out at least three months later at a main dose of 1 to 10 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are carried out at least every six months at a main dose of 1 to 10 mg / kg; or (ii) a first administration of an anti-TRBV9 antibody to a subject in need of treatment for said disease or disorder is carried out at a dose of 75 to 300 mg, a second administration of the anti-TRBV9 antibody is carried out at least three months later at a main dose of 325 to 675 mg, and subsequent administrations of the anti-TRBV9 antibody are carried out at least every six months at a main dose of 325 to 675 mg; use.

49. 49. The use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptors according to claim 48, (i) a first administration of an anti-TRBV9 antibody to a subject in need of treatment for said disease or disorder is carried out at a dose of 0.5 to 3.5 mg / kg, which is equal to half of the main dose, a second administration of the anti-TRBV9 antibody is carried out at least three months later at a main dose of 1 to 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are carried out at least every six months at a main dose of 1 to 7 mg / kg; or (ii) the first administration of the anti-TRBV9 antibody is administered at a dose of 100 to 275 mg, the second administration of the anti-TRBV9 antibody is administered at least three months later at a main dose of 350 to 650 mg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every six months at a main dose of 350 to 650 mg; use.

50. (i) the first administration of the anti-TRBV9 antibody is administered at a dose of 0.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered at least 3 months later at a dose of 1 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 6 months at a dose of 1 mg / kg; or (ii) the first administration of the anti-TRBV9 antibody is administered at a dose of 1 mg / kg, the second administration of the anti-TRBV9 antibody is administered at least 3 months later at a dose of 2 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 6 months at a dose of 2 mg / kg; or (iii) the first administration of the anti-TRBV9 antibody is administered at a dose of 1.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered at least three months later at a dose of 3 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every six months at a dose of 3 mg / kg; or (iv) the first administration of the anti-TRBV9 antibody is administered at a dose of 2.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered at least 3 months later at a dose of 5 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 6 months at a dose of 5 mg / kg; or (v) the first administration of the anti-TRBV9 antibody is administered at a dose of 3.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered at least 3 months later at a dose of 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 6 months at a dose of 7 mg / kg; 49. The use according to claim 48.

51. 49. The use of claim 48, comprising a first administration of an anti-TRBV9 antibody at a dose of 100 to 150 mg; or 225 to 275 mg, a second administration at least three months later with a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody, and subsequent administrations at least every six months with a main dose of 350 to 400 mg; or 475 to 525 mg; or 600 to 650 mg of the anti-TRBV9 antibody.

52. 49. The use of claim 48, comprising a first administration of an anti-TRBV9 antibody at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration at least three months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody, and subsequent administrations at least every six months with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg of the anti-TRBV9 antibody.

53. 49. The use of claim 48, comprising a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration at least three months later with a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg of the anti-TRBV9 antibody, and subsequent administrations of an anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least every six months to a subject in need of treatment for the disease or disorder.

54. 1. Use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor, wherein: (i) a first administration of the anti-TRBV9 antibody to a subject in need of treatment for said disease or disorder is performed at a dose of 0.5 to 5 mg / kg, which is equal to half of the main dose; a second administration of the anti-TRBV9 antibody is performed at least three months later at a main dose of 1 to 10 mg / kg; a third administration of the anti-TRBV9 antibody is performed at least six months later at a main dose of 1 to 10 mg / kg; and subsequent administrations are administered at least every 12 months at a main dose of 1 to 10 mg / kg; or (ii) a first administration of an anti-TRBV9 antibody to a subject in need of treatment for said disease or disorder is administered at a dose of 75 to 300 mg, a second administration of the anti-TRBV9 antibody is administered at least 3 months later at a main dose of 325 to 675 mg, a third administration of the anti-TRBV9 antibody is administered at least 6 months later at a main dose of 325 to 675 mg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 12 months at a main dose of 325 to 675 mg. use.

55. 55. The use of an anti-TRBV9 antibody according to claim 54 for treating a disease or disorder mediated by T lymphocytes that have a TRBV9 segment in their T cell receptor, comprising: (i) a first administration of an anti-TRBV9 antibody to a subject in need of treatment for said disease or disorder is carried out at a dose of 0.5 to 3.5 mg / kg, which is equal to half of the main dose, a second administration of the anti-TRBV9 antibody is carried out at least three months later at a main dose of 1 to 7 mg / kg, a third administration of the anti-TRBV9 antibody is carried out at least six months later at a main dose of 1 to 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are carried out at least every 12 months at a main dose of 1 to 7 mg / kg; or (ii) a first administration of an anti-TRBV9 antibody to a subject in need of treatment for said disease or disorder is carried out at a dose of 100 to 275 mg, a second administration of the anti-TRBV9 antibody is carried out at least 3 months later with a main dose of 350 to 650 mg, a third administration of the anti-TRBV9 antibody is carried out at least 6 months later with a main dose of 350 to 650 mg, and subsequent administrations of the anti-TRBV9 antibody are carried out at least every 12 months with a main dose of 350 to 650 mg; use.

56. (i) a first administration of the anti-TRBV9 antibody is administered at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody is administered at least 3 months later at a dose of 1 mg / kg, a third administration of the anti-TRBV9 antibody is administered at least 6 months later at a dose of 1 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 12 months at a dose of 1 mg / kg; or (ii) the first administration of the anti-TRBV9 antibody is administered at a dose of 1 mg / kg, the second administration of the anti-TRBV9 antibody is administered at least 3 months later at a dose of 2 mg / kg, the third administration of the anti-TRBV9 antibody is administered at least 6 months later at a dose of 2 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 12 months at a dose of 2 mg / kg; or (iii) the first administration of the anti-TRBV9 antibody is administered at a dose of 1.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered at least 3 months later at a dose of 3 mg / kg, the third administration of the anti-TRBV9 antibody is administered at least 6 months later at a dose of 3 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 12 months at a dose of 3 mg / kg; or (iv) the first administration of the anti-TRBV9 antibody is administered at a dose of 2.5 mg / kg, the second administration of the anti-TRBV9 antibody is administered at least 3 months later at a dose of 5 mg / kg, the third administration of the anti-TRBV9 antibody is administered at least 6 months later at a dose of 5 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 12 months at a dose of 5 mg / kg; or (v) The method of claim 54, wherein a first administration of an anti-TRBV9 antibody to a subject in need of treatment for the disease or disorder is administered at a dose of 3.5 mg / kg, a second administration of the anti-TRBV9 antibody is administered at least 3 months later at a dose of 7 mg / kg, a third administration of the anti-TRBV9 antibody is administered at least 6 months later at a dose of 7 mg / kg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 12 months at a dose of 7 mg / kg.

57. 55. The use of claim 54, comprising a first administration to a subject in need of treatment for the disease or disorder, the first administration being carried out at a dose of 100-150 mg; or 225-275 mg; a second administration at least three months later with a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg of the anti-TRBV9 antibody, a third administration at least six months later with a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg of the anti-TRBV9 antibody, and subsequent administrations at least every 12 months with a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg of the anti-TRBV9 antibody.

58. 55. The use of claim 54, wherein a first administration of an anti-TRBV9 antibody to a subject in need of treatment for the disease or disorder is administered at a dose of 115 to 135 mg; or 240 to 260 mg, a second administration of the anti-TRBV9 antibody is administered at least three months later with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg, a third administration of the anti-TRBV9 antibody is administered at least six months later with a dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg, and subsequent administrations of the anti-TRBV9 antibody are administered at least every 12 months with a main dose of 365 to 385 mg; or 490 to 510 mg; or 615 to 635 mg.

59. or 620 mg; or 625 mg; or 630 mg, and or 620 mg; or 625 mg; or 630 mg at least 6 months later, and subsequent administration of the anti-TRBV9 antibody is performed at least every 12 months with a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg.

60. The anti-TRBV9 antibody 1) (a) HCDR1 having the amino acid sequence of SEQ ID NO: 1; (b) an HCDR2 having the amino acid sequence of SEQ ID NO: 2; and (c) an HCDR3 having an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO:

6. a heavy chain variable domain comprising: 2) (a) an LCDR1 having the amino acid sequence of SEQ ID NO: 7; (b) an LCDR2 having the amino acid sequence of SEQ ID NO: 8; and (c) an LCDR3 having the amino acid sequence of SEQ ID NO: 9 a light chain variable domain comprising 55. The use according to any one of claims 35, 48 and 54, comprising:

61. The anti-TRBV9 antibody 1) (a) HCDR1 having the amino acid sequence of SEQ ID NO: 1; (b) an HCDR2 having the amino acid sequence of SEQ ID NO: 2; and (c) HCDR3 having the amino acid sequence of SEQ ID NO: 4 a heavy chain variable domain comprising: 2) (a) an LCDR1 having the amino acid sequence of SEQ ID NO: 7; (b) an LCDR2 having the amino acid sequence of SEQ ID NO: 8; and (c) an LCDR3 having the amino acid sequence of SEQ ID NO: 9 a light chain variable domain comprising 61. The use of claim 60, comprising:

62. The use of claim 60, wherein the anti-TRBV9 antibody is a full-length antibody and is of the human IgG1, IgG2, IgG3, or IgG4 isotype.

63. The use of claim 60, wherein the anti-TRBV9 antibody comprises a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 14 and a light chain variable domain having the amino acid sequence of SEQ ID NO: 17; or a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 15 and a light chain variable domain having the amino acid sequence of SEQ ID NO:

17.

64. The use of claim 60, wherein the anti-TRBV9 antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 22 and a light chain having the amino acid sequence of SEQ ID NO: 25; or a heavy chain having the amino acid sequence of SEQ ID NO: 23 and a light chain having the amino acid sequence of SEQ ID NO:

25.

65. 55. The use of any one of claims 35, 48, and 54, wherein the disease or disorder mediated by T lymphocytes having a TRBV9 segment in their T cell receptor is selected from the group comprising arthropathy, inflammatory bowel disease, eye diseases, systemic vasculitis, circulatory system diseases, kidney diseases, digestive system diseases, and lymphoproliferative disorders.

66. 55. The use of any one of claims 35, 48, and 54, wherein the disease or disorder mediated by T lymphocytes harboring a TRBV9 segment in their T cell receptor is selected from the group consisting of spondyloarthritis, sacroiliitis associated with psoriasis, sacroiliitis associated with inflammatory bowel disease, undiagnosed oligoarthropathy, juvenile spondylitis / enthesitis-associated arthritis, juvenile ankylosing spondylitis (enthesitis-associated arthritis), juvenile arthritis, undiagnosed juvenile arthritis, ulcerative colitis, Crohn's disease, non-infectious uveitis, anterior uveitis, Behcet's disease, aortitis, fibrosis of the aortic and / or mitral valve leaflets with regurgitation, rhythm disorders, conduction disorders, left ventricular dysfunction, pericarditis, myocarditis, IgA nephropathy, celiac disease, T-cell lymphoma, and T-cell leukemia.

67. 67. The use of claim 66, wherein the spondyloarthritis is axial spondyloarthritis meeting radiographic criteria (ankylosing spondylitis), axial spondyloarthritis not meeting radiographic criteria, axial spondyloarthritis, peripheral spondyloarthritis, psoriatic arthritis, spondyloarthritis associated with inflammatory bowel disease, reactive arthritis, or undiagnosed peripheral spondyloarthritis.

68. 67. The use of claim 66, wherein the spondyloarthritis is axial spondyloarthritis (ankylosing spondylitis) meeting radiographic criteria in patients who do not respond adequately to standard treatment, axial spondyloarthritis not meeting radiographic criteria in patients who do not respond adequately to standard treatment, axial spondyloarthritis in patients who do not respond adequately to standard treatment, peripheral spondyloarthritis in patients who do not respond adequately to standard treatment, psoriatic arthritis in patients who do not respond adequately to standard treatment, spondyloarthritis associated with inflammatory bowel disease in patients who do not respond adequately to standard treatment, reactive arthritis in patients who do not respond adequately to standard treatment, or undiagnosed peripheral spondyloarthritis in patients who do not respond adequately to standard treatment.

Images